R156. Commerce, Occupational and Professional Licensing.
R156-17b. Pharmacy Practice Act Rule.
R156-17b-101. Title.
This rule is known as the "Pharmacy Practice Act Rule".

R156-17b-102. Definitions.
In addition to the definitions in Title 58, Chapters 1 and 17b, as used in Title 58, Chapters 1 and 17b or this rule:
(1) "Accredited by ASHP" means a program that:
(a) was accredited by the ASHP on the day the applicant for licensure completed the program; or
(b) was in ASHP candidate status on the day the applicant for licensure completed the program.
(2) "ACPE" means the American Council on Pharmaceutical Education or Accreditation Council for Pharmacy Education.
(3) "Analytical laboratory":
(a) means a facility in possession of prescription drugs for the purpose of analysis; and
(b) does not include a laboratory possessing prescription drugs used as standards and controls in performing drug monitoring
or drug screening analysis if the prescription drugs are pre-diluted in a human or animal body fluid, human or animal body fluid
components, organic solvents, or inorganic buffers at a concentration not exceeding one milligram per milliliter when labeled or
otherwise designated as being for in-vitro diagnostic use.
(4) "ASHP" means the American Society of Health System Pharmacists.
(5) "Authorized distributor of record" means a pharmaceutical wholesaler with whom a manufacturer has established an
ongoing relationship to distribute the manufacturer's prescription drugs. An ongoing relationship is deemed to exist between such
pharmaceutical wholesaler and a manufacturer, as defined in Section 1504 of the Internal Revenue Code, when the pharmaceutical
wholesaler has a written agreement currently in effect with the manufacturer evidencing such ongoing relationship, and the
pharmaceutical wholesaler is listed on the manufacturer's current list of authorized distributors of record.
(6) "Authorized personnel" means any person who is a part of the pharmacy staff who participates in the operational
processes of the pharmacy and contributes to the natural flow of pharmaceutical care.
(7) "Chain pharmacy warehouse" means a physical location for prescription drugs that acts as a central warehouse and
performs intracompany sales or transfers of the prescription drugs to a group of chain pharmacies that have the same common
ownership and control.
(8) "Clinic" as used in Subsection 58-17b-625(3)(b) means a class B pharmacy, or a facility which provides out-patient
health care services whose primary practice includes the therapeutic use of drugs related to a specific patient for the purpose of:
(a) curing or preventing the patient's disease;
(b) eliminating or reducing the patient's disease;
(c) arresting or slowing a disease process.
(9) "Co-licensed partner" means a person that has the right to engage in the manufacturing or marketing of a co-licensed
product.
(10) "Co-licensed product" means a device or prescription drug for which two or more persons have the right to engage in
the manufacturing, marketing, or both consistent with FDA's implementation of the Prescription Drug Marketing Act as applicable.
(11) "Community pharmacy" as used in Subsection 58-17b-625(3)(b) means a class A pharmacy as defined in Subsection
58-17b-102(10).
(12) "Cooperative pharmacy warehouse" means a physical location for drugs that acts as a central warehouse and is owned,
operated or affiliated with a group purchasing organization (GPO) or pharmacy buying cooperative and distributes those drugs
exclusively to its members.
(13) "Counterfeit prescription drug" has the meaning given that term in 21 USC 321(g)(2), including any amendments
thereto.
(14) "Counterfeiting" means engaging in activities that create a counterfeit prescription drug.
(15) "Dispense", as defined in Subsection 58-17b-102(22), does not include transferring medications for a patient from a
legally dispensed prescription for that particular patient into a daily or weekly drug container to facilitate the patient taking the correct
medication.
(16) "Device" means an instrument, apparatus, implement, machine, contrivance, implant, or other similar or related article,
including any component part or accessory, which is required under Federal law to bear the label, "Caution: Federal or State law
requires dispensing by or on the order of a physician."
(17) "DMP" means a dispensing medical practitioner licensed under Section 58-17b, Part 8.
(18) "DMP designee" means an individual, acting under the direction of a DMP, who:
(a) holds an active health care professional license under one of the following chapters:
A Chapter 67, Utah Medical Practice Act;
B Chapter 68, Utah Osteopathic Medical Practice Act;
C Chapter 70a, Physician Assistant Act;
D Chapter 31b, Nurse Practice Act;
E Chapter 16a, Utah Optometry Practice Act;
(F) Chapter 44a, Nurse Midwife Practice Act; or
(G) Chapter 17b, Pharmacy Practice Act; or
(ii) is a medical assistant as defined in Subsection 58-67-102 (9);
(b) meets requirements established in Subsection 58-17b-803 (4)(c); and
(c) can document successful completion of a formal or on-the-job dispensing training program that meets standards
established in Section R156-17b-622.

(19) "DMPIC" means a dispensing medical practitioner licensed under Section 58-17b, Part 8 who is designated by a dispensing medical practitioner clinic pharmacy to be responsible for activities of the pharmacy.

(20) "Drop shipment" means the sale of a prescription drug to a pharmaceutical wholesaler by the manufacturer of the drug; by the manufacturer's co-licensed product partner, third party logistics provider, or exclusive distributor; or by an authorized distributor of record that purchased the product directly from the manufacturer or from one of these entities; whereby:
(a) the pharmaceutical wholesale distributor takes title to but not physical possession of such prescription drug;
(b) the pharmaceutical wholesale distributor invoices the pharmacy, pharmacy warehouse, or other person authorized by law to dispense to administer such drug; and
(c) the pharmacy, pharmacy warehouse, or other person authorized by law to dispense or administer such drug receives delivery of the prescription drug directly from the manufacturer; from the co-licensed product partner, third party logistics provider, or exclusive distributor; or from an authorized distributor of record that purchases the product directly from the manufacturer or from one of these entities.

(21) "Drug therapy management" means the review of a drug therapy regimen of a patient by one or more pharmacists for the purpose of evaluating and rendering advice to one or more practitioners regarding adjustment of the regimen.

(22) "Drugs", as used in this rule, means drugs or devices.

(23) "Durable medical equipment" or "DME" means equipment that:
(a) can withstand repeated use;
(b) is primarily and customarily used to serve a medical purpose;
(c) generally is not useful to a person in the absence of an illness or injury;
(d) is suitable for use in a health care facility or in the home; and
(e) may include devices and medical supplies.

(24) "Entities under common administrative control" means an entity holds the power, actual as well as legal to influence the management, direction, or functioning of a business or organization.

(25) "Entities under common ownership" means entity assets are held indivisibly rather than in the names of individual members.

(26) "ExCPT", as used in this rule, means the Exam for the Certification of Pharmacy Technicians.

(27) "FDA" means the United States Food and Drug Administration and any successor agency.

(28) "FDA-approved" means the federal Food, Drug, and Cosmetic Act, 21 U.S.C.A. Section 301 et seq. and regulations promulgated thereunder permit the subject drug or device to be lawfully manufactured, marketed, distributed, and sold.

(29) "High-risk, medium-risk, and low-risk drugs" refers to the risk to a patient's health from compounding sterile preparations, as referred to in USP-NF Chapter 797, for details of determining risk level.

(30) "Hospice facility pharmacy" means a pharmacy that supplies drugs to patients in a licensed healthcare facility for terminal patients.

(31) "Hospital clinic pharmacy" means a pharmacy that is located in an outpatient treatment area where a pharmacist or pharmacy intern is compounding, admixing, or dispensing prescription drugs, and where:
(a) prescription drugs or devices are under the control of the pharmacist, or the facility for administration to patients of that facility;
(b) prescription drugs or devices are dispensed by the pharmacist or pharmacy intern; or
(c) prescription drugs are administered in accordance with the order of a practitioner by an employee or agent of the facility.

(32) "Legend drug" or "prescription drug" means any drug or device that has been determined to be unsafe for self-medication or any drug or device that bears or is required to bear the legend:
(a) "Caution: federal law prohibits dispensing without prescription";
(b) "Caution: federal law restricts this drug to use by or on the order of a licensed veterinarian"; or
(c) "Rx only".

(33) "Long-term care facility" as used in Section 58-17b-610.7 means the same as the term is defined in Section 58-31b-102.

(34) "Maintenance medications" means medications the patient takes on an ongoing basis.

(35) "Manufacturer's exclusive distributor" means an entity that contracts with a manufacturer to provide or coordinate warehousing, distribution, or other services on behalf of a manufacturer and who takes title to that manufacturer's prescription drug, but who does not have general responsibility to direct the drug's sale or disposition. Such manufacturer's exclusive distributor shall be licensed as a pharmaceutical wholesaler under this chapter and be an "authorized distributor of record" to be considered part of the "normal distribution channel".

(36) "Medical supplies" means items for medical use that are suitable for use in a health care facility or in the home and that are disposable or semi-disposable and are non-reusable.
3

(37) "MPJE" means the Multistate Jurisprudence Examination.
(38) "NABP" means the National Association of Boards of Pharmacy.
(39) "NAPLEX" means North American Pharmacy Licensing Examination.
(40) "Non drug or device handling central prescription processing pharmacy" means a central prescription processing pharmacy that does not engage in compounding, packaging, labeling, dispensing, or administering of drugs or devices.
(41) "Normal distribution channel" means a chain of custody for a prescription drug that goes directly, by drop shipment as defined in Subsection (19), or via intracompany transfer from a manufacturer; or from the manufacturer's co-licensed partner, third-party logistics provider, or the exclusive distributor to:
(a) a pharmacy or other designated persons authorized under this chapter to dispense or administer prescription drugs to a patient;
(b) a chain pharmacy warehouse that performs intracompany sales or transfers of such drugs to a group of pharmacies under common ownership and control;
(c) a cooperative pharmacy warehouse to a pharmacy that is a member of the pharmacy buying cooperative or GPO to a patient;
(d) an authorized distributor of record, and then to either a pharmacy or other designated persons authorized under this chapter to dispense or administer such drug for use by a patient;
(e) an authorized distributor of record, and then to a chain pharmacy warehouse that performs intracompany sales or transfers of such drugs to a group of pharmacies under common ownership and control; or
(f) an authorized distributor of record to another authorized distributor of record to a licensed pharmaceutical facility or a licensed healthcare practitioner authorized under this chapter to dispense or administer such drug for use by a patient.
(42) "Other health care facilities" means any entity as defined in Utah Code Subsection 26-21-2(13)(a) or Utah Administrative Code R432-1-3(55).
(43) "Parenteral" means a method of drug delivery injected into body tissues but not via the gastrointestinal tract.
(44) "Patient's agent" means a:
(a) relative, friend or other authorized designee of the patient involved in the patient's care; or
(b) if requested by the patient or the individual under Subsection (40)(a), one of the following facilities:
(i) an office of a licensed prescribing practitioner in Utah;
(ii) a long-term care facility where the patient resides; or
(iii) a hospital, office, clinic or other medical facility that provides health care services.
(45) "Pedigree" means a document or electronic file containing information that records each distribution of any given prescription drug.
(46) "PIC", as used in this rule, means the pharmacist-in-charge.
(47) "Prepackaged" or "Prepackaging" means the act of transferring a drug, manually or by use of an automated pharmacy system, from a manufacturer's or distributor's original container to another container in advance of receiving a prescription drug order or for a patient's immediate need for dispensing by a pharmacy or practitioner authorized to dispense in the establishment where the prepackaging occurred.
(48) "Prescription files" means all hard-copy and electronic prescriptions that includes pharmacist notes or technician notes, clarifications or information written or attached that is pertinent to the prescription.
(49) "PTCB" means the Pharmacy Technician Certification Board.
(50) "Qualified continuing education", as used in this rule, means continuing education that meets the standards set forth in Section R156-17b-309.
(51) "Refill" means to fill again.
(52) "Repackage" means repackaging or otherwise changing the container, wrapper, or labeling to further the distribution of a prescription drug, excluding that completed by the pharmacist or DMP responsible for dispensing the product to a patient.
(53) "Research facility" means a facility where research takes place that has policies and procedures describing such research.
(54) "Reverse distributor" means a person or company that retrieves unusable or outdated drugs from a pharmacy for the purpose of removing those drugs from stock and destroying them.
(55) "Sterile products preparation facility" means any facility, or portion of the facility, that compounds sterile products using aseptic technique.
(56) "Supervisor" means a licensed pharmacist or DMP in good standing with the Division.
(57) "Third party logistics provider" means anyone who contracts with a prescription drug manufacturer to provide or coordinate warehousing, distribution, or other similar services on behalf of a manufacturer, but does not take title to the prescription drug or have any authoritative control over the prescription drug's sale.
(58) "Unauthorized personnel" means any person who is not participating in the operational processes of the pharmacy who in some way would interrupt the natural flow of pharmaceutical care.
(59) "Unit dose" means the ordered amount of a drug in a dosage form prepared for a one-time administration to an individual and indicates the name, strength, lot number and beyond use date for the drug.
(60) "Unprofessional conduct", as defined in Title 58, Chapters 1 and 17b, is further defined, in accordance with Subsection
58-1-203(1)(e), in Section R156-17b-502.
(61) "USP-NF" means the United States Pharmacopeia-National Formulary (USP 40-NF 35), either First Supplement, dated August 1, 2017, or Second Supplement, dated December 1, 2017, which is hereby adopted and incorporated by reference.
(62) "Wholesaler" means a wholesale distributor who supplies or distributes drugs or medical devices that are restricted by federal law to sales based on the order of a physician to a person other than the consumer or patient.
(63) "Wholesale distribution" means the distribution of drugs to persons other than consumers or patients, but does not include:
(a) intracompany sales or transfers;
(b) the sale, purchase, distribution, trade, or other transfer of a prescription drug for emergency medical reasons, as defined under 21 CFR 203.3(m), including any amendments thereto;
(c) the sale, purchase, or trade of a drug pursuant to a prescription;
(d) the distribution of drug samples;
(e) the return or transfer of prescription drugs to the original manufacturer, original wholesale distributor, reverse distributor, or a third party returns processor;
(f) the sale, purchase, distribution, trade, or transfer of a prescription drug from one authorized distributor to another authorized distributor of record for a time period for which there is documentation from the manufacturer that the manufacturer is able to supply a prescription drug and the supplying authorized distributor of record in writing that the prescription drug was supplied at the time when it was exclusively in the normal distribution channel;
(g) the sale, purchase or exchange of blood or blood components for transfusions;
(h) the sale, transfer, merger or consolidation of all or part of the business of a pharmacy;
(i) delivery of a prescription drug by a common carrier; or
(j) other transactions excluded from the definition of "wholesale distribution" under 21 CFR 203.3 (cc), including any amendments thereto.

R156-17b-103. Authority - Purpose.
This rule is adopted by the Division under the authority of Subsection 58-1-106(1)(a) to enable the Division to administer Title 58, Chapter 17b.

R156-17b-104. Organization - Relationship to Rule R156-1.
The organization of this rule and its relationship to Rule R156-1 is as described in Section R156-1-107.

R156-17b-105. Licensure - Administrative Inspection.
In accordance with Subsection 58-17b-103(3)(f), the procedure for disposing of any drugs or devices seized by the Division during an administrative inspection shall be handled as follows:
(1) Any legal drugs or devices found and temporarily seized by the Division that are found to be in compliance with this chapter shall be returned to the PIC or DMPIC of the pharmacy involved at the conclusion of any investigative or adjudicative proceedings and appeals.
(2) Any drugs or devices that are temporarily seized by the Division that are found to be unlawfully possessed, adulterated, misbranded, outdated, or otherwise in violation of this rule shall be destroyed by Division personnel at the conclusion of any investigative or adjudicative proceedings and appeals. The destruction of any seized controlled substance drugs shall be witnessed by two Division individuals. A controlled substance destruction form shall be completed and retained by the Division.
(3) An investigator may, upon determination that the violations observed are of a nature that pose an imminent peril to the public health, safety and welfare, recommend to the Division Director to issue an emergency licensure action, such as cease and desist.
(4) In accordance with Subsections 58-17b-103(3) and 58-17b-601(1), a secure email address must be established by the PIC or DMPIC and responsible party for the pharmacy to be used for self-audits or pharmacy alerts initiated by the Division. The PIC or DMPIC and responsible party shall cause the Division's Licensing Bureau to be notified on the applicable form prescribed by the Division of the secure email address or any change thereof within seven days of any email address change. Only one email address shall be used for each pharmacy.

R156-17b-302. Pharmacy Licensure Classifications - Pharmacist-in-Charge orDispensing Medical Practitioner-In-Charge Requirements.
In accordance with Subsection 58-17b-302(4), the classification of pharmacies holding licenses are clarified as:
(1) A Class A pharmacy includes all retail operations located in Utah and requires a PIC.
(2) A Class B pharmacy includes an institutional pharmacy that provides services to a target population unique to the needs of the healthcare services required by the patient. All Class B pharmacies require a PIC or DMPIC except for pharmaceutical administration facilities and narcotic treatment program pharmacies. Examples of Class B pharmacies include:
(a) closed door pharmacies;
(b) hospital clinic pharmacies;
(c) narcotic treatment program pharmacies;
(d) nuclear pharmacies;
(e) branch pharmacies;
(f) hospice facility pharmacies;
(g) pharmaceutical administration facility pharmacies;
(h) sterile product preparation facility pharmacies; and
(i) dispensing medical practitioner clinic pharmacies.

(3) A Class C pharmacy includes a pharmacy that is involved in:
(a) manufacturing;
(b) producing;
(c) wholesaling;
(d) distributing; or
(e) reverse distributing.

(4) A Class D pharmacy requires a PIC licensed in the state where the pharmacy is located and includes an out-of-state mail order pharmacy. Facilities with multiple locations shall have licenses for each facility and each component part of a facility.

(5) A Class E pharmacy does not require a PIC and includes:
(a) analytical laboratory pharmacies;
(b) animal control pharmacies;
(c) durable medical equipment provider pharmacies;
(d) human clinical investigational drug research facility pharmacies;
(e) medical gas provider pharmacies;
(f) animal narcotic detection training facility pharmacies
(g) third party logistics providers;
(h) non drug or device handling central prescription processing pharmacies; and
(i) veterinarian pharmaceutical facility pharmacies.

(6) All pharmacy licenses shall be converted to the appropriate classification by the Division as identified in Section 58-17b-302.

(7) Each Class A and each Class B pharmacy required to have a PIC or DMPIC shall have one PIC or DMPIC who is employed on a full-time basis as defined by the employer, who acts as a PIC or DMPIC for one pharmacy. However, the PIC or DMPIC may be the PIC or DMPIC of more than one Class A or Class B pharmacy, if the additional Class A or Class B pharmacies are not open to provide pharmacy services simultaneously.

(8) A PIC or DMPIC shall comply with the provisions of Section R156-17b-603.

R156-17b-303a. Qualifications for Licensure - Education Requirements.

(1) In accordance with Subsections 58-17b-303(2) and 58-17b-304(7)(b), the credentialing agency recognized to provide certification and evaluate equivalency of a foreign educated pharmacy graduate is the Foreign Pharmacy Graduate Examination Committee (FPGEC) of the National Association of Boards of Pharmacy Foundation.

(2) In accordance with Subsection 58-17b-304(7), an applicant for a pharmacy intern license shall demonstrate that he meets one of the following education criteria:
(a) current admission in a College of Pharmacy accredited by the ACPE by written verification from the Dean of the College;
(b) a graduate degree from a school or college of pharmacy that is accredited by the ACPE; or
(c) a graduate degree from a foreign pharmacy school as established by a certificate of equivalency from an approved credentialing agency defined in Subsection (1).

(3) In accordance with Subsection 58-17b-305(1)(f), a pharmacy technician shall complete a training program that is:
(a) accredited by ASHP; or
(b) conducted by:
   (i) the National Pharmacy Technician Association;
   (ii) Pharmacy Technicians University; or
   (iii) a branch of the Armed Forces of the United States, and
(c) meets the following standards:
   (i) completion of at least 180 hours of directly supervised practical training in a licensed pharmacy as determined appropriate by a licensed pharmacist in good standing; and
   (ii) written protocols and guidelines for the teaching pharmacist outlining the utilization and supervision of pharmacy technician trainees that address:
       (A) the specific manner in which supervision will be completed; and
       (B) an evaluative procedure to verify the accuracy and completeness of all acts, tasks and functions performed by the pharmacy technician trainee.

(4) An individual shall complete a pharmacy technician training program and successfully pass the required examination as listed in Subsection R156-17b-303c(4) within two years after obtaining a pharmacy technician trainee license, unless otherwise
approved by the Division in collaboration with the Board for good cause showing exceptional circumstances.
   (a) Unless otherwise approved under Subsection (4), an individual who fails to apply for and obtain a pharmacy technician license within the two-year time frame shall repeat a pharmacy technician training program in its entirety if the individual pursues licensure as a pharmacy technician.

   (5)(a) Pharmacy technician training programs that received Division approval on or before April 30, 2014 are exempt from satisfying standards established in Subsection R156-17b-303a(3) for students enrolled on or before December 31, 2018.
   (b) A student in a program described in Subsection (5)(a) shall comply with the program completion deadline and testing requirements in Subsection (4), except that the license application shall be submitted to the Division no later than December 31, 2021.
   (c) A program in ASHP candidate status shall notify a student prior to enrollment that if the program is denied accreditation status while the student is enrolled in the program, the student will be required to complete education in another program with no assurance of how many credits will transfer to the new program.
   (d) A program in ASHP candidate status that is denied accreditation shall immediately notify the Division, enrolled students and student practice sites, of the denial. The notice shall instruct each student and practice site that:
      (i) the program no longer satisfies the pharmacy technician license education requirement in Utah; and
      (ii) enrollment in a different program meeting requirements established in Subsection R156-17b-303a(3) is necessary for the student to complete training and to satisfy the pharmacy technician license education requirement in Utah.
   (6) An applicant from another jurisdiction seeking licensure as a pharmacy technician in Utah is deemed to have met the qualifications for licensure in Subsection 58-17b-305(1)(f) and 58-17b-305(1)(g) if the applicant:
      (a) has engaged in the practice of a pharmacy technician for a minimum of 1,000 hours in that jurisdiction within the past two years or has equivalent experience as approved by the Division in collaboration with the Board; and
      (b) has passed and maintained current PTCB or ExCPT certification.

R156-17b-303b. Licensure - Pharmacist - Pharmacy Internship Standards.
   In accordance with Subsection 58-17b-303(1)(g), the following standards are established for the pharmacy internship required for licensure as a pharmacist:
   (1) For graduates of all U.S. pharmacy schools:
      (a) At least 1,740 hours of practice supervised by a pharmacy preceptor shall be obtained in Utah or another state or territory of the United States, or a combination of both according to the Accreditation Council for Pharmacy Education (ACPE), Accreditation Standards and Guidelines for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree Guidelines Version 2.0 Effective February 14, 2011, which is hereby incorporated by reference.
      (b) Introductory pharmacy practice experiences (IPPE) shall account for not less than 300 hours over the first three professional years.
      (c) A minimum of 150 hours shall be balanced between community pharmacy and institutional health system settings.
      (d) Advanced pharmacy practice experiences (APPE) shall include at least 1,440 hours (i.e., 36 weeks) during the last academic year and after all IPPE requirements are completed.
      (e) Required experiences shall:
         (i) include primary, acute, chronic, and preventive care among patients of all ages; and
         (ii) develop pharmacist-delivered patient care competencies in the community pharmacy, hospital or health-system pharmacy, ambulatory care, inpatient/acute care, and general medicine settings.
      (f) Internship hours completed in another state or territory of the United States shall be accepted based on the approval of the hours by the pharmacy board in the jurisdiction where the hours were obtained.
      (g) Evidence of completed internship hours shall be documented to the Division by the pharmacy intern at the time application is made for a Utah pharmacist license.
      (h) Pharmacy interns participating in internships may be credited no more than 50 hours per week of internship experience.
         (i) No credit will be awarded for didactic experience.
      (j) If a pharmacy intern is suspended or dismissed from an approved College of Pharmacy, the intern shall notify the Division within 15 days of the suspension or dismissal.
      (k) If a pharmacy intern ceases to meet all requirements for intern licensure, the pharmacy intern shall surrender the pharmacy intern license to the Division within 60 days unless an extension is requested and granted by the Division in collaboration with the Board.
   (2) For graduates of all foreign pharmacy schools, at least 1,440 hours of supervised pharmacy practice in the United States.
   (3) Up to 500 hours towards the requirements of Subsections (1)(a) or (2) may be granted, at the discretion of the Division in collaboration with the Board, for other experience substantially related to the practice of pharmacy.

R156-17b-303c. Qualifications for Licensure - Examinations.
   (1) In accordance with Subsection 58-17b-303(1)(h), the examinations that shall be successfully passed by an applicant for licensure as a pharmacist are:
      (a) the NAPLEX with a passing score as established by NABP; and
      (b) the Multistate Pharmacy Jurisprudence Examination (MPJE) with a minimum passing score as established by NABP.
(2) An individual who has failed either examination twice shall meet with the Board to request an additional authorization to test. The Division, in collaboration with the Board, may require additional training as a condition for approval of an authorization to retest.

(3) In accordance with Subsection 58-17b-303(3)(j), an applicant applying by endorsement is required to pass the MPJE.

(4) In accordance with Subsection 58-17b-305(1)(g), an applicant applying for licensure as a pharmacy technician shall pass the PTCB or ExCPT with a passing score as established by the certifying body. The certificate shall exhibit a valid date and that the certification is active.

(5) A graduate of a foreign pharmacy school shall obtain a passing score on the Foreign Pharmacy Graduate Examination Committee (FPGEC) examination.

R156-17b-303d. Qualifications for Licensure - Meet with the Board.
In accordance with Subsections 58-1-202(1)(d) and 58-1-301(3), an applicant for licensure under Title 58, Chapter 17b may be required to meet with the Board of Pharmacy for the purpose of evaluating the applicant's qualifications for licensure.

R156-17b-304. Temporary Licensure.
(1) In accordance with Subsection 58-1-303(1), the Division may issue a temporary pharmacist license to a person who meets all qualifications for licensure as a pharmacist in Utah except for the passing of the required examination, if the applicant:
   (a) is a graduate of an ACPE accredited pharmacy school within two months immediately preceding application for licensure, enrolled in a pharmacy graduate residency or fellowship program, or licensed, in good standing, to practice pharmacy in another state or territory of the United States;
   (b) submit a complete application for licensure as a pharmacist except the passing of the NAPLEX and MJPE examinations;
   (c) submits evidence of having secured employment conditioned upon issuance of the temporary license, and the employment is under the direct, on-site supervision of a pharmacist with an active, non-temporary license that may or may not include a controlled substance license; and
   (d) has registered to take the required licensure examinations.

(2) A temporary pharmacist license issued under Subsection (1) expires the earlier of:
   (a) six months from the date of issuance;
   (b) the date upon which the Division receives notice from the examination agency that the individual has failed either examination twice; or
   (c) the date upon which the Division issues the individual full licensure.

(3) An individual who has failed either examination twice shall meet with the Board to request an additional authorization to test. The Division, in collaboration with the Board, may require additional training as a condition for approval of an authorization to retest.

(4) A pharmacist temporary license issued in accordance with this section cannot be renewed or extended.

R156-17b-305. Licensure - Pharmacist by Endorsement.
(1) In accordance with Subsections 58-17b-303(3) and 58-1-301(3), an applicant for licensure as a pharmacist by endorsement shall apply through the "Licensure Transfer Program" administered by NABP.

(2) An applicant for licensure as a pharmacist by endorsement does not need to provide evidence of intern hours if that applicant has:
   (a) lawfully practiced as a licensed pharmacist a minimum of 2,000 hours in the four years immediately preceding application in Utah;
   (b) obtained sufficient continuing education credits required to maintain a license to practice pharmacy in the state of practice; and
   (c) not had a pharmacist license suspended, revoked, canceled, surrendered, or otherwise restricted for any reason in any state for ten years prior to application in Utah, unless otherwise approved by the Division in collaboration with the Board.

R156-17b-307. Qualifications for Licensure - Criminal Background Checks.
(1) An applicant for licensure as a pharmacy shall document to the satisfaction of the Division the owners and management of the pharmacy and the facility in which the pharmacy is located.

(2) The following individuals associated with an applicant for licensure as a pharmacy shall be subject to the criminal background check requirements set forth in Section 58-17b-307:
   (a) the PIC;
   (b) the PIC's immediate supervisor;
   (c) the senior person in charge of the facility in which the pharmacy is located;
   (d) others associated with management of the pharmacy or the facility in which the pharmacy is located as determined necessary by the Division in order to protect public health, safety and welfare; and
   (e) owners of the pharmacy or the facility in which the pharmacy is located as determined necessary by the Division in order to protect public health, safety and welfare.
R156-17b-308. Renewal Cycle - Procedures.

(1) In accordance with Subsection 58-1-308(1), the renewal date for the two-year renewal cycle applicable to licensees under Title 58, Chapter 17b is established by rule in Section R156-1-308a.

(2) Renewal procedures shall be in accordance with Section R156-1-308c.

(3) An intern license may be extended upon the request of the licensee and approval by the Division under the following conditions:
   (a) the intern applied to the Division for a pharmacist license and to sit for the NAPLEX and MJPE examinations within three calendar months after obtaining full certification from the Foreign Pharmacy Graduate Equivalency Commission; or
   (b) the intern lacks the required number of internship hours for licensure.

R156-17b-309. Continuing Education.

(1) In accordance with Section 58-17b-310 and Subsections 58-1-203(1)(g) and 58-1-308(3)(b), there is created a requirement for continuing education as a condition for renewal or reinstatement of a pharmacist or pharmacy technician license issued under Title 58, Chapter 17b.

(2) Requirements shall consist of the following number of qualified continuing education hours in each preceding renewal period:
   (a) 30 hours for a pharmacist; and
   (b) 20 hours for a pharmacy technician.

(3) The required number of hours of qualified continuing professional education for an individual who first becomes licensed during the two year renewal cycle shall be decreased in a pro-rata amount equal to any part of that two year period preceding the date on which that individual first became licensed.

(4) Qualified continuing professional education hours shall consist of the following:
   (a) for pharmacists:
      (i) institutes, seminars, lectures, conferences, workshops, various forms of mediated instruction, and programmed learning courses, presented by an institution, individual, organization, association, corporation or agency that has been approved by ACPE;
      (ii) programs approved by health-related continuing education approval organizations provided the continuing education is nationally recognized by a healthcare accrediting agency and the education is related to the practice of pharmacy;
      (iii) programs of certification by qualified individuals, such as certified diabetes educator credentials, board certification in advanced therapeutic disease management or other certification as approved by the Division in consultation with the Board; and
      (iv) training or educational presentations offered by the Division.
   (b) for pharmacy technicians:
      (i) institutes, seminars, lectures, conferences, workshops, various forms of mediated instruction, and programmed learning courses, presented by an institution, individual, organization, association, corporation or agency that has been approved by ACPE;
      (ii) programs approved by health-related continuing education approval organizations provided the continuing education is nationally recognized by a healthcare accrediting agency and the education is related to the practice of pharmacy; and
      (iii) educational meetings that meet ACPE continuing education criteria sponsored by the Utah Pharmacist Association, the Utah Society of Health-System Pharmacists or other professional organization or association; and
      (iv) training or educational presentations offered by the Division.

(5) Credit for qualified continuing professional education shall be recognized in accordance with the following:
   (a) Pharmacists:
      (i) a minimum of 12 hours shall be obtained through attendance at live or technology enabled participation lectures, seminars or workshops;
      (ii) a minimum of 15 hours shall be in drug therapy or patient management; and
      (iii) a minimum of one hour shall be in pharmacy law or ethics.
   (b) Pharmacy Technicians:
      (i) a minimum of eight hours shall be obtained through attendance at live or technology enabled participation at lectures, seminars or workshops; and
      (ii) a minimum of one hour shall be in pharmacy law or ethics.
      (iii) documentation of current PTCB or ExCPT certification will count as meeting the requirement for continuing education.

(6) A licensee shall be responsible for maintaining competent records of completed qualified continuing professional education for a period of four years after the close of the two year period to which the records pertain. It is the responsibility of the licensee to maintain such information with respect to qualified continuing professional education to demonstrate it meets the requirements under this section.


(1) An individual licensed as a pharmacy intern who is currently under disciplinary action and qualifies for licensure as a pharmacist may be issued a pharmacist license under the same restrictions as the pharmacy intern license.

(2) A pharmacist, pharmacy intern, pharmacy technician, pharmacy technician trainee, or DMP whose license or registration
is suspended under Subsection 58-17b-701(6) may petition the Division at any time to demonstrate the ability to resume competent practice.

**R156-17b-402. Administrative Penalties.**

In accordance with Subsection 58-17b-401(6) and Sections 58-17b-501 and 58-17b-502, unless otherwise ordered by the presiding officer, the following fine and citation schedule shall apply:

1. preventing or refusing to permit any authorized agent of the Division to conduct an inspection, in violation of Subsection 58-17b-501(1):
   - initial offense: $500 - $2,000
   - subsequent offense(s): $5,000
2. failing to deliver the license or permit or certificate to the Division upon demand, in violation Subsection 58-17b-501(2):
   - initial offense: $100 - $1,000
   - subsequent offense(s): $500 - $2,000
3. using the title pharmacist, druggist, pharmacy intern, pharmacy technician, pharmacy technician trainee or any other term having a similar meaning or any term having similar meaning when not licensed to do so, in violation of Subsection 58-17b-501(3)(a):
   - initial offense: $500 - $2,000
   - subsequent offense(s): $2,000 - $10,000
4. conducting or transacting business under a name that contains as part of that name the words drugstore, pharmacy, drugs, medicine store, medicines, drug shop, apothecary, prescriptions or any other term having a similar meaning or in any manner advertising otherwise describing or referring to the place of the conducted business or profession when not licensed to do so, in violation of Subsection 58-17b-501(3)(b):
   - initial offense: $500 - $2,000
   - subsequent offense(s): $2,000 - $10,000
5. buying, selling, causing to be sold, or offering for sale any drug or device that bears the inscription sample, not for resale, investigational purposes, or experimental use only or other similar words inspection, in violation of Subsection 58-17b-501(4):
   - initial offense: $1,000 - $5,000
   - subsequent offense(s): $10,000
6. using to the licensee's own advantage or revealing to anyone other than the Division, Board or its authorized representatives, any information acquired under the authority of this chapter concerning any method or process that is a trade secret, in violation of Subsection 58-17b-501(5):
   - initial offense: $100 - $500
   - subsequent offense(s): $200 - $1,000
7. illegally procuring or attempting to procure any drug for the licensee or to have someone else procure or attempt to procure a drug, in violation of Subsection 58-17b-501(6):
   - initial offense: $500 - $2,000
   - subsequent offense(s): $2,000 - $10,000
8. filling, refilling or advertising the filling or refilling of prescription drugs when not licensed do to so, in violation of Subsection 58-17b-501(7):
   - initial offense: $500 - $2,000
   - subsequent offense(s): $2,000 - $10,000
9. requiring any employed pharmacist, pharmacy intern, pharmacy technician, pharmacy technician trainee or authorized supportive personnel to engage in any conduct in violation of this chapter, in violation of Subsection 58-17b-501(8):
   - initial offense: $500 - $2,000
   - subsequent offense(s): $2,500 - $10,000
10. being in possession of a drug for an unlawful purpose, in violation of Subsection 58-17b-501(9):
    - initial offense: $500 - $1,000
    - subsequent offense(s): $1,500 - $5,000
11. dispensing a prescription drug to anyone who does not have a prescription from a practitioner or to anyone who is known or should be known as attempting to obtain drugs by fraud or misrepresentation, in violation of Subsection 58-17b-501(10):
    - initial offense: $500 - $2,000
    - subsequent offense(s): $2,500 - $10,000
12. selling, dispensing or otherwise trafficking in prescription drugs when not licensed to do so or when not exempted from licensure, in violation of Subsection 58-17b-501(11):
    - initial offense: $1,000 - $5,000
    - subsequent offense(s): $10,000
13. using a prescription drug or controlled substance for the licensee that was not lawfully prescribed for the licensee by a practitioner, in violation of Subsection 58-17b-501(12):
    - initial offense: $100 - $500
    - subsequent offense(s): $1,000 - $2,5000
(14) willfully deceiving or attempting to deceive the Division, the Board or its authorized agents as to any relevant matter regarding compliance under this chapter, in violation of Subsection 58-17b-502(1):

- initial offense: $500 - $2,000
- subsequent offense(s): $2,500 - $10,000

(15) paying rebates to practitioners or any other health care provider, or entering into any agreement with a medical practitioner or any other person for the payment or acceptance of compensation for recommending the professional services of either party, in violation of Subsection 58-17b-502(2):

- initial offense: $2,500 - $5,000
- subsequent offense(s): $5,500 - $10,000

(16) misbranding or adulteration of any drug or device or the sale, distribution or dispensing of any outdated, misbranded, or adulterated drugs or devices, in violation of Subsection 58-17b-502(3):

- initial offense: $1,000 - $5,000
- subsequent offense(s): $10,000

(17) engaging in the sale or purchase of drugs that are samples or packages bearing the inscription “sample” or “not for resale” or similar words or phrases, in violation of Subsection 58-17b-502(4):

- initial offense: $500 - $2,000
- subsequent offense(s): $2,500 - $10,000

(18) accepting back and redistributing any unused drugs, with the exception as provided in Section 58-17b-503, in violation of Subsection 58-17b-502(5):

- initial offense: $1,000 - $5,000
- subsequent offense(s): $10,000

(19) engaging in an act in violation of this chapter committed by a person for any form of compensation if the act is incidental to the person’s professional activities, including the activities of a pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee in violation of Subsection 58-17b-502(6):

- initial offense: $500 - $2,000
- subsequent offense(s): $2,500 - $10,000

(20) violating Federal Title II, PL 91, Controlled Substances Act or Title 58, Chapter 37, Utah Controlled Substances Act, or rules and regulations adopted under either act, in violation of Subsection 58-17b-502(7):

- initial offense: $500 - $2,000
- subsequent offense(s): $2,500 - $10,000

(21) requiring or permitting pharmacy interns, pharmacy technicians, or pharmacy technician trainees to engage in activities outside the scope of practice for their respective license classifications, or beyond their scopes of training and ability, in violation of Subsection 58-17b-502(8):

- initial offense: $100 - $500
- subsequent offense(s): $500 - $1,000

(22) administering without appropriate training, guidelines, lawful order, or in conflict with a practitioner’s written guidelines or protocol for administering, in violation of Subsection 58-17b-502(9):

- initial offense: $500 - $2,000
- subsequent offense(s): $2,000 - $10,000

(23) disclosing confidential patient information in violation of the provision of the Health Insurance Portability and Accountability Act of 1996 or other applicable law, in violation of Subsection 58-17b-502(10):

- initial offense: $100 - $500
- subsequent offense(s): $500 - $1,000

(24) engaging in the practice of pharmacy without a licensed pharmacist designated as the PIC, in violation of Subsection 58-17b-502(11):

- initial offense: $100 - $500
- subsequent offense(s): $2,000 - $10,000

(25) failing to report to the Division any adverse action taken by another licensing jurisdiction, government agency, law enforcement agency or court, in violation of Subsection 58-17b-502(12):

- initial offense: $100 - $500
- subsequent offense(s): $500 - $1,000

(26) preparing a prescription drug in a dosage form that is regularly and commonly available from a manufacturer in quantities and strengths prescribed by a practitioner, in violation of Subsection 58-17b-502(13):

- initial offense: $500 - $1,000
- subsequent offense(s): $2,500 - $5,000

(27) violating any ethical code provision of the American Pharmaceutical Association Code of Ethics for Pharmacists, October 27, 1994, in violation of Subsection R156-17b-502(1):

- initial offense: $250 - $500
- subsequent offense(s): $2,000 - $10,000
(28) failing to comply with USP-NF Chapter 795 guidelines, in violation of Subsection R156-17b-502(2):
   initial offense: $250 - $500
   subsequent offense(s): $500 - $750
(29) failing to comply with USP-NF Chapter 797 guidelines, in violation of Subsection R156-17b-502(2):
   initial offense: $500 - $2,000
   subsequent offense(s) $2,500 - $10,000
(30) failing to comply with the continuing education requirements set forth in this rule, in violation of Subsection R156-17b-502(3):
   initial offense: $100 - $500
   subsequent offense(s): $500 - $1,000
(31) failing to provide the Division with a current mailing address within 10 days following any change of address, in violation of Subsection R156-17b-502(4):
   initial offense: $50 - $100
   subsequent offense(s): $200 - $300
(32) defaulting on a student loan, in violation of Subsection R156-17b-502(5):
   initial offense: $100 - $200
   subsequent offense(s) $200 - $500
(33) failing to abide by all applicable federal and state law regarding the practice of pharmacy, in violation of Subsection R156-17b-502(6):
   initial offense: $500 - $1,000
   subsequent offense(s): $2,000 - $10,000
(34) failing to comply with administrative inspections, in violation of Subsection R156-17b-502(7):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,000 - $10,000
(35) failing to return a self-inspection report according to the deadline established by the Division, or providing false information on a self-inspection report, in violation of Subsection R156-17b-502(8):
   initial offense: $100 - $250
   subsequent offense(s): $300 - $500
(36) violating the laws and rules regulating operating standards in a pharmacy discovered upon inspection by the Division, in violation of Subsection R156-17b-502(9):
   initial violation: $50 - $100
   failure to comply within determined time: $250 - $500
   subsequent violations: $250 - $500
   failure to comply within established time: $750 - $1,000
(37) abandoning a pharmacy and/or leaving drugs accessible to the public, in violation of Subsection R156-17b-502(10):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,000 - $10,000
(38) failing to identify license classification when communicating by any means, in violation of Subsection R156-17b-502(11):
   initial offense: $100 - $500
   subsequent offense(s): $500 - $1,000
(39) failing to maintain an appropriate ratio of personnel, in violation of Subsection R156-17b-502(12):
   Pharmacist initial offense: $100 - $250
   Pharmacist subsequent offense(s): $500 - $2,500
   Pharmacy initial offense: $250 - $1,000
   Pharmacy subsequent offense(s): $500 - $5,000
(40) allowing any unauthorized persons in the pharmacy, in violation of Subsection R156-17b-502(13):
   Pharmacist initial offense: $50 - $100
   Pharmacist subsequent offense(s): $250 - $500
   Pharmacy initial offense: $250 - $500
   Pharmacy subsequent offense(s): $1,000 - $2,000
(41) failing to offer to counsel any person receiving a prescription medication, in violation of Subsection R156-17b-502(14):
   Pharmacy personnel initial offense: $500 - $2,500
   Pharmacy personnel subsequent offense(s): $5,000 - $10,000
   Pharmacy: $2,000 per occurrence
(42) failing to pay an administrative fine within the time designated by the Division, in violation of Subsection R156-17b-502(15):
   Double the original penalty amount up to $10,000
(43) failing to comply with the PIC or DMPIC standards as established in Section R156-17b-603, in violation of Subsection
R156-17b-502(16):
initial offense: $500 - $2,000
subsequent offense(s) $2,000 - $10,000
(44) failing to take appropriate steps to avoid or resolve identified drug therapy management problems as referenced in Subsection R156-17b-611(3), in violation of Subsection R156-17b-502(17):
initial offense: $500 - $2,500
subsequent offense: $5,000 - $10,000
(45) dispensing a medication that has been discontinued by the FDA, in violation of Subsection R156-17b-502(18):
initial offense: $100 - $500
subsequent offense: $200 - $1,000
(46) failing to keep or report accurate records of training hours, in violation of Subsection R156-17b-502(19):
initial offense: $100 - $500
subsequent offense: $200 - $1,000
(47) failing to provide PIC or DMPIC information to the Division within 30 days of a change in PIC or DMPIC, in violation of Subsection R156-17b-502(20):
initial offense: $100 - $500
subsequent offense: $200 - $1,000
(48) requiring a pharmacy, PIC, or any other pharmacist to operate a pharmacy with unsafe personnel ratio, in violation of Subsection R156-17b-502(21):
initial offense: $500 - $2,000
subsequent offense: $2,000 - $10,000
(49) failing to update the Division within seven calendar days of any change in the email address designated for use in self-audits or pharmacy alerts, in violation of Subsection R156-17b-502(22):
Pharmacist initial offense: $100 - $300
Pharmacist subsequent offense(s): $500 - $1,000
Pharmacy initial offense: $250 - $500
Pharmacy subsequent offense(s): $500 - $1,250
(50) practicing or attempting to practice as a pharmacist, pharmacist intern, pharmacy technician, or pharmacy technician trainee or operating a pharmacy without a license, in violation of Subsection 58-1-501(1)(a):
initial offense: $500 - $2,000
subsequent offense(s): $2,000 - $10,000
(51) impersonating a licensee or practicing under a false name, in violation of Subsection 58-1-501(1)(b):
initial offense: $500 - $2,000
subsequent offense(s): $2,000 - $10,000
(52) knowingly employing an unlicensed person, in violation of Subsection 58-1-501(1)(c):
initial offense: $500 - $1,000
subsequent offense(s): $1,000 - $5,000
(53) knowingly permitting the use of a license by another person, in violation of Subsection 58-1-501(1)(d):
initial offense: $500 - $1,000
subsequent offense(s): $1,000 - $5,000
(54) obtaining a passing score, applying for or obtaining a license or otherwise dealing with the Division or Board through the use of fraud, forgery, intentional deception, misrepresentation, misstatement, or omission, in violation of Subsection 58-1-501(1)(e):
initial offense: $100 - $2,000
subsequent offense(s): $2,000 - $10,000
(55) issuing a prescription without prescriptive authority conferred by a license or an exemption to licensure, in violation of Subsection 58-1-501(1)(f)(i)(A)and 58-1-501(2)(m)(i):
initial offense: $500 - $2,000
subsequent offense(s): $2,000 - $10,000
(56) issuing a prescription without prescriptive authority conferred by a license or an exemption to licensure without obtaining information sufficient to establish a diagnosis, identify underlying conditions and contraindications to treatment in a situation other than an emergency or an on-call cross coverage situation, in violation of Subsection 58-1-501(1)(f)(i)(B)and 58-1-501(2)(m)(ii):
initial offense: $500 - $2,000
subsequent offense(s): $2,000 - $10,000
(57) violating or aiding or abetting any other person to violate any statute, rule or order regulating pharmacy, in violation of Subsection 58-1-501(2)(a):
initial offense: $100 - $2,000
subsequent offense(s): $2,000 - $10,000
(58) violating or aiding or abetting any other person to violate any generally accepted professional or ethical standard, in violation of Subsection 58-1-501(2)(b):
  initial offense: $500 - $2,000
  subsequent offense(s): $2,000 - $10,000
(59) engaging in conduct that results in conviction of, or a plea of nolo contendere, or a plea of guilty or nolo contendere held in abeyance to a crime, in violation of Subsection 58-1-501(2)(c):
  initial offense: $500 - $2,000
  subsequent offense(s): $2,000 - $10,000
(60) engaging in conduct that results in disciplinary action by any other jurisdiction or regulatory authority, that if the conduct had occurred in this state, would constitute grounds for denial of licensure or disciplinary action, in violation of Subsection 58-1-501(2)(d):
  initial offense: $100 - $500
  subsequent offense(s): $200 - $1,000
(61) engaging in conduct, including the use of intoxicants, drugs, or similar chemicals, to the extent that the conduct does or may impair the ability to safely engage in practice as a pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee, in violation of Subsection 58-1-501(2)(e):
  initial offense: $100 - $500
  subsequent offense(s): $200 - $1,000
(62) practicing or attempting to practice as a pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee when physically or mentally unfit to do so, in violation of Subsection 58-1-501(2)(f):
  initial offense: $100 - $500
  subsequent offense(s): $200 - $1,000
(63) practicing or attempting to practice as a pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee through gross incompetence, gross negligence or a pattern of incompetency or negligence, in violation of Subsection 58-1-501(2)(g):
  initial offense: $500 - $2,000
  subsequent offense(s): $2,000 - $10,000
(64) practicing or attempting to practice as a pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee by any form of action or communication that is false, misleading, deceptive or fraudulent, in violation of Subsection 58-1-501(2)(h):
  initial offense: $100 - $500
  subsequent offense(s): $200 - $1,000
(65) practicing or attempting to practice as a pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee beyond the individual's scope of competency, abilities or education, in violation of Subsection 58-1-501(2)(i):
  initial offense: $100 - $500
  subsequent offense(s): $200 - $1,000
(66) practicing or attempting to practice as a pharmacist, pharmacy intern, pharmacy technician, or pharmacy technician trainee beyond the scope of licensure, in violation of Subsection 58-1-501(2)(j):
  initial offense: $100 - $500
  subsequent offense(s): $200 - $1,000
(67) verbally, physically or mentally abusing or exploiting any person through conduct connected with the licensee's practice, in violation of Subsection 58-1-501(2)(k):
  initial offense: $100 - $1,000
  subsequent offense(s): $500 - $2,000
(68) acting as a supervisor without meeting the qualification requirements for that position as defined by statute or rule, in violation of Subsection 58-1-501(2)(l):
  initial offense: $100 - $500
  subsequent offense(s): $200 - $1,000
(69) violating a provision of Section 58-1-501.5, in violation of Subsection 58-1-501(2)(n):
  initial offense: $500 - $2,000
  subsequent offense(s): $2,000 - $10,000
(70) surrendering licensure to any other licensing or regulatory authority having jurisdiction over the licensee or applicant in the same occupation or profession while an investigation or inquiry into allegations of unprofessional or unlawful conduct is in progress or after a charging document has been filed against the applicant or licensee alleging unprofessional or unlawful conduct, in violation of Subsection R156-1-501(1):
  initial offense: $500 - $2,000
  subsequent offense(s): $2,500 - $10,000
(71) practicing a regulated occupation or profession in, through, or with a limited liability company that has omitted the words, “limited company,” “limited liability company,” or the abbreviation “L.C.” or “L.L.C.” in the commercial use of the name of
the limited liability company, in violation of Subsection R156-1-501 (2):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(72) practicing a regulated occupation or profession in, through, or with a limited partnership that has omitted the words,
“limited partnership,” “limited,” or the abbreviation “L.P.” or “L.td.” in the commercial use of the name of the limited partnership, in
violation of Subsection R156-1-501(3):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(73) practicing a regulated occupation or profession in, through, or with a professional corporation that has omitted the words
“professional corporation” or the abbreviation “P.C.” in the commercial use of the name of the professional corporation, in
violation of Subsection R156-1-501(4):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(74) using a capitalized DBA (doing-business-as name) that has not been properly registered with the Division of
Corporations and with the Division of Occupational and Professional Licensing, in violation of Subsection R156-1-501(5):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(75) failing, as a prescribing practitioner, to follow the “Model Policy for the Use of Controlled Substances for the Treatment
of Pain,” May 2004, established by the Federation of State Medical Boards of the United States, Inc., which is hereby adopted and
incorporated by reference, in violation of Subsection R156-1-501(6):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(76) engaging in prohibited acts as defined in Section 58-37-8, in violation of Section 58-37-8:
   initial offense: $1,000 - $5,000
   subsequent offense(s) $5,000 - $10,000
(77) self-prescribing or self-administering by a licensee of any Schedule II or Schedule III controlled substance that is not
prescribed by another practitioner having authority to prescribe the drug, in violation of Subsection R156-37-502(1)(a):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(78) prescribing or administering a controlled substance for a condition that the licensee is not licensed or competent to treat, in
violation of Subsection R156-37-502(1)(b):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(79) violating any federal or state law relating to controlled substances, in violation of Subsection R156-37-502(2):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(80) failing to deliver to the Division all controlled substance certificates issued by the Division, to the Division, upon an
action that revokes, suspends, or limits the license, in violation of R156-37-502(3):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(81) failing to maintain controls over controlled substances that would be considered by a prudent licensee to be effective
against diversion, theft, or shortage of controlled substances, in violation of Subsection R156-37-502(4):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(82) being unable to account for shortages of controlled substances in any controlled substances inventory for which the
licensee has responsibility, in violation of Subsection R156-37-502(5):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(83) knowingly prescribing, selling, giving away, or administering, directly or indirectly, or offering to sell, furnish, give
away, or administer any controlled substance to a drug dependent person, as defined in Subsection 58-37-2(1)(s), except for legitimate
medical purposes as permitted by law, in violation of Subsection R156-37-502(6):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(84) refusing to make available for inspection controlled substance stock, inventory, and records as required under this rule
or other law regulating controlled substances and controlled substance records, in violation of Subsection R156-37-502(7):
   initial offense: $500 - $2,000
   subsequent offense(s): $2,500 - $10,000
(85) failing to submit controlled substance prescription information to the database manager after being notified in writing to
do so, in violation of Subsection R156-37-502(8):
(86) any other conduct that constitutes unprofessional or unlawful conduct:
initial offense: $100 - $500
subsequent offense(s): $200 - $1,000

(87) if licensed as a DMP or DMP clinic pharmacy, delegating the dispensing of a drug to a DMP designee who has not completed a formal or on-the-job dispensing training program that meets standards established in Section R156-17b-622, in violation of Subsection R156-17b-502 (25):
initial offense: $500 - $2,000
subsequent offense: $2,500 - $10,000

R156-17b-502. Unprofessional Conduct.
"Unprofessional conduct" includes:
(1) violating any provision of the American Pharmaceutical Association (APhA) Code of Ethics for Pharmacists, October 27, 1994, which is hereby incorporated by reference;
(2) failing to comply with the USP-NF Chapters 795 and 797 if such chapters are applicable to activities performed in the pharmacy;
(3) failing to comply with the continuing education requirements set forth in these rules;
(4) failing to provide the Division with a current mailing address within a 10 business day period of time following any change of address;
(5) defaulting on a student loan;
(6) failing to abide by all applicable federal and state law regarding the practice of pharmacy;
(7) failing to comply with administrative inspections;
(8) failing to return according to the deadline established by the Division, or providing false information on a self-inspection report;
(9) violating the laws and rules regulating operating standards in a pharmacy discovered upon inspection by the Division;
(10) abandoning a pharmacy or leaving prescription drugs accessible to the public;
(11) failing to identify licensure classification when communicating by any means;
(12) practicing pharmacy with an inappropriate pharmacist to pharmacy intern ratio established by Subsection R156-17b-606(1)(d) or pharmacist to pharmacy technician ratio as established by Subsection R156-17b-601(3);
(13) allowing any unauthorized persons in the pharmacy;
(14) failing to offer to counsel any person receiving a prescription medication;
(15) failing to pay an administrative fine that has been assessed in the time designated by the Division;
(16) failing to comply with the PIC or DMPIC standards as established in Section R156-17b-603;
(17) failing to adhere to institutional policies and procedures related to technician checking of medications when technician checking is utilized;
(18) failing to take appropriate steps to avoid or resolve identified drug therapy management problems as referenced in Subsection R156-17b-611(3);
(19) dispensing medication that has been discontinued by the FDA;
(20) failing to keep or report accurate records of training hours;
(21) failing to provide PIC or DMPIC information to the Division within 30 days of a change in PIC or DMPIC;
(22) requiring a pharmacy, pharmacist, or DMP to operate the pharmacy or allow operation of the pharmacy with a ratio of supervising pharmacist or DMP to other pharmacy personnel in circumstances that result in, or reasonably would be expected to result in, an unreasonable risk of harm to public health, safety, and welfare;
(23) failing to update the Division within seven calendar days of any change in the email address designated for use in self-audits or pharmacy alerts;
(24) failing to ensure, as a DMP or DMP clinic pharmacy, that a DMP designee has completed a formal or on-the-job dispensing training program that meets standards established in Section R156-17b-622; and
(25) failing to make a timely report regarding dispensing of an opiate antagonist to the division and to the physician who issued the standing order as required in Section R156-17b-625.

R156-17b-601. Operating Standards - Pharmacy Technician and Pharmacy Technician Trainee.
In accordance with Subsection 58-17b-102(56), practice as a licensed pharmacy technician is defined as follows:
(1) A pharmacy technician may perform any task associated with the physical preparation and processing of prescription and medication orders including:
(a) receiving written prescriptions;
(b) taking refill orders;
(c) entering and retrieving information into and from a database or patient profile;
(d) preparing labels;
(e) retrieving medications from inventory;
(f) counting and pouring into containers;
(g) placing medications into patient storage containers;
(h) affixing labels;
(i) compounding;
(j) counseling for over-the-counter drugs and dietary supplements under the direction of the supervising pharmacist as referenced in Subsection 58-17b-102(56);
(k) accepting new prescription drug orders left on voicemail for a pharmacist to review;
(l) performing checks of certain medications prepared for distribution filled or prepared by another technician within a Class B hospital pharmacy, such as medications prepared for distribution to an automated dispensing cabinet, cart fill, crash cart medication tray, or unit dosing from a prepared stock bottle, in accordance with the following operating standards:
   (i) technicians authorized by a hospital to check medications shall have at least one year of experience working as a pharmacy technician and at least six months experience at the hospital where the technician is authorized to check medications;
   (ii) technicians shall only check steps in the medication distribution process that do not require the professional judgment of a pharmacist and that are supported by sufficient automation or technology to ensure accuracy (e.g. barcode scanning, drug identification automation, checklists, visual aids);
   (iii) hospitals that authorize technicians to check medications shall have a training program and ongoing competency assessment that is documented and retrievable for the duration of each technician's employment and at least three years beyond employment, and shall maintain a list of technicians on staff that are allowed to check medications;
   (iv) hospitals that authorize technicians to check medications shall have a medication error reporting system in place and shall be able to produce documentation of its use;
   (v) a supervising pharmacist shall be immediately available during all times that a pharmacy technician is checking medications;
   (vi) hospitals that authorize technicians to check medications shall have comprehensive policies and procedures that guide technician checking that include the following:
      (A) process for technician training and ongoing competency assessment and documentation;
      (B) process for supervising technicians who check medications;
      (C) list of medications, or types of medications that may or may not be checked by a technician;
      (D) description of the automation or technology to be utilized by the institution to augment the technician check;
      (E) process for maintaining a permanent log of the unique initials or identification codes that identify each technician responsible for checked medications by name; and
      (F) description of processes used to track and respond to medication errors; and
    (m) additional tasks not requiring the judgment of a pharmacist.
(2) A pharmacy technician trainee may perform any task in Subsection (1) with the exception of performing checks of certain medications prepared for distribution filled or prepared by another technician within a Class B hospital pharmacy as described in Subsection (1)(l).
(3)  The pharmacy technician shall not receive new prescriptions or medication orders as described in Subsection 58-17b-102(b)(iv), clarify prescriptions or medication orders nor perform drug utilization reviews. A new prescription, as used in Subsection 58-17b-102(b)(iv), does not include authorization of a refill of a legend drug.
(4) Pharmacy technicians shall have general supervision by a pharmacist in accordance with Subsection R156-17b-603(3)(s).
(5) A pharmacy technician trainee shall practice only under the direct supervision of a pharmacist and in a ratio not to exceed one pharmacy technician trainee to one pharmacist.

R156-17b-602. Operating Standards - Pharmacy Intern.
A pharmacy intern may provide services including the practice of pharmacy under the supervision of an approved preceptor, as defined in Subsection 58-17b-102(50), provided the pharmacy intern met the criteria as established in Subsection R156-17b-306.

R156-17b-603. Operating Standards - Pharmacist-In-Charge or Dispensing-Medical-Practitioner-In-Charge.
(1) The PIC or DMPIC shall have the responsibility to oversee the operation of the pharmacy in conformance with all laws and rules pertinent to the practice of pharmacy and the distribution of drugs, durable medical equipment and medical supplies. The PIC or DMPIC shall be personally in full and actual charge of the pharmacy.
(2) In accordance with Subsections 58-17b-103(1) and 58-17b-601(1), a unique email address shall be established by the PIC, DMPIC, or responsible party for the pharmacy to be used for self-audits or pharmacy alerts initiated by the Division. The PIC, DMPIC, or responsible party shall notify the Division of the pharmacy's email address in the initial application for licensure.
(3) The duties of the PIC or DMPIC shall include:
   (a) assuring that a pharmacist, pharmacy intern, DMP, or DMP designee dispenses drugs or devices, including:
      (i) packaging, preparation, compounding and labeling; and
   (ii) ensuring that drugs are dispensed safely and accurately as prescribed;
(b) assuring that pharmacy personnel deliver drugs to the patient or the patient's agent, including ensuring that drugs are delivered safely and accurately as prescribed;
(c) assuring that a pharmacist, pharmacy intern, or DMP communicates to the patient or the patient's agent, at their request, information concerning any prescription drugs dispensed to the patient by the pharmacist, pharmacy intern, or DMP;
(d) assuring that a reasonable effort is made to obtain, record and maintain patient medication records;
(e) education and training of pharmacy personnel;
(f) establishment of policies for procurement of prescription drugs and devices and other products dispensed from the pharmacy;
(g) disposal and distribution of drugs from the pharmacy;
(h) bulk compounding of drugs;
(i) storage of all materials, including drugs, chemicals and biologicals;
(j) maintenance of records of all transactions of the pharmacy necessary to maintain accurate control over and accountability for all pharmaceutical materials required by applicable state and federal laws and regulations;
(k) establishment and maintenance of effective controls against theft or diversion of prescription drugs and records for such drugs;
(l) if records are kept on a data processing system, the maintenance of records stored in that system shall be in compliance with pharmacy requirements;
(m) legal operation of the pharmacy including meeting all inspection and other requirements of all state and federal laws, rules and regulations governing the practice of pharmacy;
(n) implementation of an ongoing quality assurance program that monitors performance of the automated pharmacy system, which is evidenced by written policies and procedures developed for pharmaceutical care;
(o) if permitted to use an automated pharmacy system for dispensing purposes:
(i) ensuring that the system is in good working order and accurately dispenses the correct strength, dosage form and quantity of the drug prescribed while maintaining appropriate record keeping and security safeguards; and
(ii) implementation of an ongoing quality assurance program that monitors performance of the automated pharmacy system, which is evidenced by written policies and procedures developed for pharmaceutical care;
(p) assuring that all relevant information is submitted to the Controlled Substance Database in the appropriate format and in a timely manner;
(q) assuring that all pharmacy personnel have the appropriate licensure;
(r) assuring that no pharmacy operates with a ratio of pharmacist or DMP to other pharmacy personnel circumstances that result in, or reasonably would be expected to result in, an unreasonable risk of harm to public health, safety, and welfare;
(s) assuring that the PIC or DMPIC assigned to the pharmacy is recorded with the Division and that the Division is notified of a change in PIC or DMPIC within 30 days of the change; and
(i) assuring, with regard to the unique email address used for self-audits and pharmacy alerts, that:
(ii) the pharmacy uses a single email address; and
(iii) the pharmacy notifies the Division, on the form prescribed, of any change in the email address within seven calendar days of the change.

R156-17b-604. Operating Standards - Closing a Pharmacy.

At least 14 days prior to the closing of a pharmacy, the PIC or DMPIC shall comply with the following:
(1) If the pharmacy is registered to possess controlled substances, send a written notification to the appropriate regional office of the Drug Enforcement Administration (DEA) containing the following information:
(a) the name, address and DEA registration number of the pharmacy;
(b) the anticipated date of closing;
(c) the name, address and DEA registration number of the pharmacy acquiring the controlled substances; and
(d) the date the transfer of controlled substances will occur.
(2) If the pharmacy dispenses prescription drug orders, post a closing notice sign in a conspicuous place in the front of the prescription department and at all public entrance doors to the pharmacy. Such closing notice shall contain the following information:
(a) the date of closing; and
(b) the name, address and telephone number of the pharmacy acquiring the prescription drug orders, including refill information and patient medication records of the pharmacy.
(3) On the date of closing, the PIC or DMPIC shall remove all prescription drugs from the pharmacy by one or a combination of the following methods:
(a) return prescription drugs to manufacturer or supplier for credit or disposal; or
(b) transfer, sell or give away prescription drugs to a person who is legally entitled to possess drugs, such as a hospital or another pharmacy.
(4) If the pharmacy dispenses prescription drug orders:
(a) transfer the prescription drug order files, including refill information and patient medication records, to a licensed pharmacy within a reasonable distance of the closing pharmacy; and
(b) move all signs or notify the landlord or owner of the property that it is unlawful to use the word "pharmacy", or any other word or combination of words of the same or similar meaning, or any graphic representation that would mislead or tend to mislead the public that a pharmacy is located at this address.

(5) Within 10 days of the closing of the pharmacy, the PIC or DMPIC shall forward to the Division a written notice of the closing that includes the following information:

(a) the actual date of closing;
(b) a surrender of the license issued to the pharmacy;
(c) a statement attesting:
   (i) that an inventory as specified in Subsection R156-17b-605(4) has been conducted; and
   (ii) the manner in which the legend drugs and controlled substances possessed by the pharmacy were transferred or disposed;
(d) if the pharmacy dispenses prescription drug orders, the name and address of the pharmacy to which the prescription drug orders, including refill information and patient medication records, were transferred.

(6) If the pharmacy is registered to possess controlled substances, a letter shall be sent to the appropriate DEA regional office explaining that the pharmacy has closed. The letter shall include the following items:

(a) DEA registration certificate;
(b) all unused DEA order forms (Form 222) with the word "VOID" written on the face of each order form; and
(c) copy #2 of any DEA order forms (Form 222) used to transfer Schedule II controlled substances from the closed pharmacy.

(7) If the pharmacy is closed suddenly due to fire, destruction, natural disaster, death, property seizure, eviction, bankruptcy or other emergency circumstances and the PIC or DMPIC cannot provide notification 14 days prior to the closing, the PIC or DMPIC shall comply with the provisions of Subsection (1) as far in advance of the closing as allowed by the circumstances.

(8) If the PIC or DMPIC is not available to comply with the requirements of this section, the owner or legal representative shall be responsible for compliance with the provisions of this section.

(9) Notwithstanding the requirements of this section, a DMP clinic pharmacy that closes but employs licensed practitioners who desire to continue providing services other than dispensing may continue to use prescription drugs in their practice as authorized under their respective licensing act.

R156-17b-605. Operating Standards - Inventory Requirements.

(1) All out of date legend drugs and controlled substances shall be removed from the inventory at regular intervals and in correlation to the beyond use date imprinted on the label.

(2) General requirements for inventory of a pharmacy shall include the following:

(a) the PIC or DMPIC shall be responsible for taking all required inventories, but may delegate the performance of the inventory to another person or persons;
(b) the inventory records shall be maintained for a period of five years and be readily available for inspection;
(c) the inventory records shall be filed separately from all other records;
(d) the inventory records shall be in a written, typewritten, or printed form and include all stocks of controlled substances on hand on the date of the inventory including any that are out of date drugs and drugs in automated pharmacy systems. An inventory taken by use of a verbal recording device shall be promptly transcribed;
(e) the inventory may be taken either as the opening of the business or the close of business on the inventory date;
(f) the person taking the inventory and the PIC or DMPIC shall indicate the time the inventory was taken and shall sign and date the inventory with the date the inventory was taken. The signature of the PIC or DMPIC and the date of the inventory shall be documented within 72 hours or three working days of the completed initial, annual, change of ownership and closing inventory;
(g) the person taking the inventory shall make an exact count or measure all controlled substances listed in Schedule I or II;
(h) the person taking the inventory shall make an estimated count or measure of all Schedule III, IV or V controlled substances, unless the container holds more than 1,000 tablets or capsules in which case an exact count of the contents shall be made;
(i) the inventory of Schedule I and II controlled substances shall be listed separately from the inventory of Schedule III, IV and V controlled substances;
(j) if the pharmacy maintains a perpetual inventory of any of the drugs required to be inventories, the perpetual inventory shall be reconciled on the date of the inventory.

(3) Requirements for taking the initial controlled substances inventory shall include the following:

(a) all pharmacies having any stock of controlled substances shall take an inventory on the opening day of business. Such inventory shall include all controlled substances including any out-of-date drugs and drugs in automated pharmacy systems;
(b) in the event a pharmacy commences business with no controlled substances on hand, the pharmacy shall record this fact as the initial inventory. An inventory reporting no Schedule I and II controlled substances shall be listed separately from an inventory reporting no Schedule III, IV, and V controlled substances;
(c) the initial inventory shall serve as the pharmacy's inventory until the next completed inventory as specified in Subsection (4) of this section; and
(d) when combining two pharmacies, each pharmacy shall:
   (i) conduct a separate closing pharmacy inventory of controlled substances on the date of closure; and
   (ii) conduct a combined opening inventory of controlled substances for the new pharmacy prior to opening.
(4) Requirement for annual controlled substances inventory shall be within 12 months following the inventory date of each year and may be taken within four days of the specified inventory date and shall include all stocks including out-of-date drugs and drugs in automated pharmacy systems.

(5) Requirements for change of ownership shall include the following:
   (a) a pharmacy that changes ownership shall take an inventory of all legend drugs and controlled substances including out-of-date drugs and drugs in automated pharmacy systems on the date of the change of ownership;
   (b) such inventory shall constitute, for the purpose of this section, the closing inventory for the seller and the initial inventory for the buyer; and
   (c) transfer of Schedule I and II controlled substances shall require the use of official DEA order forms (Form 222).

(6) Requirement for taking inventory when closing a pharmacy includes the PIC, DMPIC, owner, or the legal representative of a pharmacy that ceases to operate as a pharmacy shall forward to the Division, within ten days of cessation of operation, a statement attesting that an inventory has been conducted, the date of closing and a statement attesting the manner by which legend drugs and controlled substances possessed by the pharmacy were transferred or disposed.

(7) All pharmacies shall maintain a perpetual inventory of all Schedule II controlled substances that shall be reconciled according to facility policy.

R156-17b-606. Operating Standards - Approved Preceptor.
   In accordance with Subsection 58-17b-601(1), the operating standards for a pharmacist acting as a preceptor include:
   (1) meeting the following criteria:
      (a) hold a Utah pharmacist license that is active and in good standing;
      (b) document engaging in active practice as a licensed pharmacist for not less than one year in any jurisdiction;
      (c) not be under any sanction which, when considered by the Division and Board, would be of such a nature that the best interests of the intern and the public would not be served;
      (d) provide direct, on-site supervision to:
         (i) no more than two pharmacy interns during a working shift except as provided in Subsection (ii);
         (ii) up to five pharmacy interns at public-health outreach programs such as informational health fairs, chronic disease state screening and education programs, and immunization clinics, provided:
            (A) the totality of the circumstances are safe and appropriate according to generally recognized industry standards of practice; and
            (B) the preceptor has obtained written approval from the pharmacy interns' schools of pharmacy for the intern's participation;
      (e) refer to the intern training guidelines as outlined in the Pharmacy Coordinating Council of Utah Internship Competencies, October 12, 2004, as information about a range of best practices for training interns;
   (2) maintaining adequate records to document the number of internship hours completed by the intern and evaluating the quality of the intern's performance during the internship;
   (3) completing the preceptor section of a Utah Pharmacy Intern Experience Affidavit found in the application packet at the conclusion of the preceptor/intern relationship regardless of the time or circumstances under which that relationship is concluded; and
   (4) being responsible for the intern's actions related to the practice of pharmacy while practicing as a pharmacy intern under supervision.

   (1) In accordance with Subsection 58-17b-102(69)(a), supportive personnel may assist in any tasks not related to drug preparation or processing including:
      (a) stock ordering and restocking;
      (b) cashiering;
      (c) billing;
      (d) filing;
      (e) receiving a written prescription and delivering it to the pharmacist, pharmacy intern, pharmacy technician, pharmacy technician trainee, DMP, or DMP designee;
      (f) housekeeping; and
      (g) delivering a pre-filled prescription to a patient.
   (2) Supportive personnel shall not enter information into a patient prescription profile or accept verbal refill information.
   (3) In accordance with Subsection 58-17b-102(69)(b) all supportive personnel shall be under the supervision of a licensed pharmacist or DMP. The licensed pharmacist or DMP shall be present in the area where the person being supervised is performing services and shall be immediately available to assist the person being supervised in the services being performed except for the delivery of prefilled prescriptions as provided in Subsection (1)(g) above.
   (4) In accordance with Subsection 58-17b-601(1), a pharmacist, pharmacy intern, pharmacy technician, pharmacy technician trainee, DMP, or DMP designee whose license has been revoked or is suspended shall not be allowed to provide any support services in a pharmacy.
R156-17b-608. Common Carrier Delivery.

A pharmacy that employs the United States Postal Service or other common carrier to deliver a filled prescription directly to a patient shall, under the direction of the PIC, DMPIC, or other responsible employee:

1. use adequate storage or shipping containers and shipping processes to ensure drug stability and potency. The shipping processes shall include the use of appropriate packaging material and devices, according to the recommendations of the manufacturer or the United States Pharmacopeia Chapter 1079, in order to ensure that the drug is kept at appropriate storage temperatures throughout the delivery process to maintain the integrity of the medication;
2. use shipping containers that are sealed in a manner to detect evidence of opening or tampering;
3. develop and implement policies and procedures to ensure accountability, safe delivery, and compliance with temperature requirements. The policies and procedures shall address when drugs do not arrive at their destination in a timely manner or when there is evidence that the integrity of a drug was compromised during shipment. In these instances, the pharmacy shall make provisions for the replacement of the drugs;
4. (i) provide for an electronic, telephonic, or written communication mechanism for a pharmacy to offer counseling to the patient as defined in Section 58-17b-613; and
   (ii) provide documentation of such counseling; and
5. provide information to the patient indicating what the patient should do if the integrity of the packaging or drug was compromised during shipment.


In accordance with Subsections 58-17b-601(1) and 58-17b-604(1), the following operating standards shall apply with respect to medication profile systems:

1. Patient profiles, once established, shall be maintained by a pharmacy dispensing to patients on a recurring basis for a minimum of one year from the date of the most recent prescription filled or refilled; except that a hospital pharmacy may delete the patient profile for an inpatient upon discharge if a record of prescriptions is maintained as a part of the hospital record.
2. Information to be included in the profile shall be determined by a responsible pharmacist or DMP at the pharmaceutical facility but shall include as a minimum:
   (a) full name of the patient, address, telephone number, date of birth or age and gender;
   (b) patient history where significant, including known allergies and drug reactions, and a list of prescription drugs obtained by the patient at the pharmacy including:
      (i) name of prescription drug;
      (ii) strength of prescription drug;
      (iii) quantity dispensed;
      (iv) date of filling or refilling;
      (v) charge for the prescription drug as dispensed to the patient; and
      (c) any additional comments relevant to the patient's drug use.
3. Patient medication profile information shall be recorded by a pharmacist, pharmacy intern, pharmacy technician, pharmacy technician trainee, or DMP designee.

R156-17b-610. Operating Standards - Patient Counseling.

In accordance with Subsection 58-17b-601(1), guidelines for providing patient counseling established in Section 58-17b-613 include the following:

1. Counseling shall be offered orally in person unless the patient or patient's agent is not at the pharmacy or a specific communication barrier prohibits oral communication.
2. A pharmacy facility shall orally offer to counsel but shall not be required to counsel a patient or patient's agent when the patient or patient's agent refuses such counseling.
3. Based upon the professional judgment of the pharmacist, pharmacy intern, or DMP, patient counseling may include the following elements:
   (a) the name and description of the prescription drug;
   (b) the dosage form, dose, route of administration and duration of drug therapy;
   (c) intended use of the drug, when known, and expected action;
   (d) special directions and precautions for preparation, administration and use by the patient;
   (e) common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance, and the action required if they occur;
   (f) techniques for self-monitoring drug therapy;
   (g) proper storage;
   (h) prescription refill information;
(i) action to be taken in the event of a missed dose;
(j) pharmacist comments relevant to the individual's drug therapy, including any other information specific to the patient or
drug; and
(k) the date after which the prescription should not be taken or used, or the beyond use date.

(4) The offer to counsel shall be documented and said documentation shall be available to the Division. These records shall
be maintained for a period of five years and be available for inspection within 7-10 business days.

(5) Only a pharmacist, pharmacy intern, or DMP may orally provide counseling to a patient or patient's agent and answer
questions concerning prescription drugs.

(6) If a prescription drug order is delivered to the patient or the patient's agent at the patient's or other designated location,
the following is applicable:

(a) the information specified in Subsection (3) of this section shall be delivered with the dispensed prescription in writing;
(b) if prescriptions are routinely delivered outside the area covered by the pharmacy's local telephone service, the pharmacist
shall place on the prescription container or on a separate sheet delivered with the prescription container, the telephone number of
the pharmacy and the statement "Written information about this prescription has been provided for you. Please read this
information before you take this medication. If you have questions concerning this prescription, a pharmacist is available during normal business
hours to answer these questions."; and
(c) written information provided in Subsection (6)(b) of this section shall be in the form of patient information leaflets
similar to USP-NF patient information monographs or equivalent information.

(7) Patient counseling shall not be required for inpatients of a hospital or institution where other licensed health care
professionals are authorized to administer the patient's drugs.

R156-17b-610.5. Dispensing in Emergency Department - Patient's Immediate Need.
In accordance with Section 58-17b-610.5, the guidelines for medical practitioners to dispense drugs to a patient in a hospital
emergency department are established in this section.

(1) To meet a patient's immediate needs, the prescribing practitioner may provide up to a three-day emergency supply, which
is properly labeled according to Subsection R156-17b-610.5(3).

(2) Notwithstanding Subsection R156-17b-610.5(1), the following may be provided:

(a) a seven day supply of sexually-transmitted infections (STI) prophylaxis;
(b) a Naloxone kit.

(3) Labeling of an emergency supply shall at a minimum include:

(a) prescribing practitioner's name, facility name and telephone number;
(b) patient's name;
(c) name of medication and strength;
(d) date given;
(e) instructions for use; and
(f) beyond use date.

(4) Records of controlled substances dispensed by the prescribing practitioner shall be provided to the appropriate pharmacy
so that the applicable prescription data can be reported to the Utah Controlled Substance Database.

R156-17b-610.6. Hospital Pharmacy Dispensing Prescription Drugs to Patients at Discharge to Meet a Patient's Immediate
Needs.
In accordance with Section 58-17b-610.6, the guidelines for a hospital pharmacy to dispense to an individual who is no
longer a patient, on the day discharged from the hospital setting, are established in this section.

(1) The prescription drug shall be dispensed:

(a) during regular inpatient hospital pharmacy hours, by a pharmacist; or
(b) outside of regular inpatient hospital pharmacy hours, by the prescribing practitioner using an appropriately labeled pre-
packaged drug.

(2) Labeling for a prescription under Section 58-17b-610.6 shall at a minimum include:

(a) prescribing practitioner's name, facility name, and telephone number;
(b) patient's name;
(c) name and strength of medication;
(d) date given;
(e) instructions for use; and
(f) beyond use date.

(3) Applicable data of controlled substances dispensed shall be reported to the Utah Controlled Substance Database.

R156-17b-610.7. Partial Filling of a Schedule II Controlled Substance Prescription.
In accordance with Section 58-17b-610.7, a pharmacy that partially fills a prescription for a Schedule II controlled substance
shall specify by prescription number for each partial fill the:
(a) date;
(b) quantity supplied; and
(c) quantity remaining of the prescription partially filled.

R156-17b-611. Operating Standards - Drug Therapy Management.

(1) In accordance with Subsections 58-17b-102(17) and 58-17b-601(1), decisions involving drug therapy management shall be made in the best interest of the patient. Drug therapy management may include:
   (a) implementing, modifying and managing drug therapy according to the terms of the Collaborative Pharmacy Practice Agreement;
   (b) collecting and reviewing patient histories;
   (c) obtaining and checking vital signs, including pulse, temperature, blood pressure and respiration;
   (d) ordering and evaluating the results of laboratory tests directly applicable to the drug therapy, when performed in accordance with approved protocols applicable to the practice setting; and
   (e) such other patient care services as may be allowed by rule.

(2) For the purpose of promoting therapeutic appropriateness, a pharmacist shall at the time of dispensing a prescription, or a prescription drug order, review the patient's medication record. Such review shall at a minimum identify clinically significant conditions, situations or items, such as:
   (a) inappropriate drug utilization;
   (b) therapeutic duplication;
   (c) drug-disease contraindications;
   (d) drug-drug interactions;
   (e) incorrect drug dosage or duration of drug treatment;
   (f) drug-allergy interactions; and
   (g) clinical abuse or misuse.

(3) Upon identifying any clinically significant conditions, situations or items listed in Subsection (2) above, the pharmacist shall take appropriate steps to avoid or resolve the problem including consultation with the prescribing practitioner.

R156-17b-612. Operating Standards - Prescriptions.

In accordance with Subsection 58-17b-601(1), the following shall apply to prescriptions:

(1) Prescription orders for controlled substances (including prescription transfers) shall be handled according to the rules of the Federal Drug Enforcement Administration.

(2) A prescription issued by an authorized licensed practitioner, if verbally communicated by an agent of that practitioner upon that practitioner's specific instruction and authorization, may be accepted by a pharmacist, pharmacy intern, or DMP.

(3) A prescription issued by a licensed prescribing practitioner, if electronically communicated by an agent of that practitioner, upon that practitioner's specific instruction and authorization, may be accepted by a pharmacist, pharmacy intern, pharmacy technician, pharmacy technician trainee, DMP, or DMP designee.

(4) In accordance with Sections 58-17b-609 and 58-17b-611, prescription files, including refill information, shall be maintained for a minimum of five years and shall be immediately retrievable in written or electronic format.

(5) Prescriptions for legend drugs having a remaining authorization for refill may be transferred by the pharmacist, pharmacy intern, or DMP at the pharmacy holding the prescription to a pharmacist, pharmacy intern or DMP at another pharmacy upon the authorization of the patient to whom the prescription was issued or electronically as authorized under Subsection R156-17b-613(9). The transferring pharmacist, pharmacy intern, or DMP and receiving pharmacist, pharmacy intern, or DMP shall act diligently to ensure that the total number of authorized refills is not exceeded. The following additional terms apply to such a transfer:
   (a) the transfer shall be communicated directly between pharmacists, pharmacy intern, or DMP or as authorized under Subsection R156-17b-613(9);
   (b) both the original and the transferred prescription drug orders shall be maintained for a period of five years from the date of the last refill;
   (c) the pharmacist, pharmacy intern, or DMP transferring the prescription drug order shall void the prescription electronically or write void/transfer on the face of the invalidated prescription manually;
   (d) the pharmacist, pharmacy intern, or DMP receiving the transferred prescription drug order shall:
      (i) indicate on the prescription record that the prescription was transferred electronically or manually; and
      (ii) record on the transferred prescription drug order the following information:
         (A) original date of issuance and date of dispensing or receipt, if different from date of issuance;
         (B) original prescription number and the number of refills authorized on the original prescription drug order;
         (C) number of valid refills remaining and the date of last refill, if applicable;
         (D) the name and address of the pharmacy and the name of the pharmacist, pharmacy intern, or DMP to whom such prescription is transferred; and
   (E) the name of the pharmacist, pharmacy intern, or DMP transferring the prescription drug order information;
   (e) the data processing system shall have a mechanism to prohibit the transfer or refilling of legend drugs or controlled
substance prescription drug orders that have been previously transferred; and

(f) a pharmacist, pharmacy intern, or DMP may not refuse to transfer original prescription information to another pharmacist, pharmacy intern, or DMP who is acting on behalf of a patient and who is making a request for this information as specified in Subsection (12) of this section.

(6) Prescriptions for terminal patients in licensed hospices, home health agencies or nursing homes may be partially filled if the patient has a medical diagnosis documenting a terminal illness and may not need the full prescription amount.

(7) Refills may be dispensed only in accordance with the prescriber's authorization as indicated on the original prescription drug order;

(8) If there are no refill instructions on the original prescription drug order, or if all refills authorized on the original prescription drug order have been dispensed, authorization from the prescribing practitioner shall be obtained prior to dispensing any refills.

(9) Refills of prescription drug orders for legend drugs may not be refilled after one year from the date of issuance of the original prescription drug order without obtaining authorization from the prescribing practitioner prior to dispensing any additional quantities of the drug.

(10) Refills of prescription drug orders for controlled substances shall be done in accordance with Subsection 58-37-6(7)(f).

(11) A pharmacist or DMP may exercise professional judgment in refilling a prescription drug order for a drug, other than a controlled substance listed in Schedule II, without the authorization of the prescribing practitioner, provided:

(a) failure to refill the prescription might result in an interruption of a therapeutic regimen or create patient suffering;

(b) either:

(i) a natural or manmade disaster has occurred that prohibits the pharmacist or DMP from being able to contact the practitioner; or

(ii) the pharmacist or DMP is unable to contact the practitioner after a reasonable effort, the effort should be documented and said documentation should be available to the Division;

(c) the quantity of prescription drug dispensed does not exceed a 72-hour supply, unless the packaging is in a greater quantity;

(d) the pharmacist or DMP informs the patient or the patient's agent at the time of dispensing that the refill is being provided without such authorization and that authorization of the practitioner is required for future refills;

(e) the pharmacist or DMP informs the practitioner of the emergency refill at the earliest reasonable time;

(f) the pharmacist or DMP maintains a record of the emergency refill containing the information required to be maintained on a prescription as specified in this subsection; and

(g) the pharmacist or DMP affixes a label to the dispensing container as specified in Section 58-17b-602.

(12) If the prescription was originally filled at another pharmacy, the pharmacist or DMP may exercise his professional judgment in refilling the prescription provided:

(a) the patient has the prescription container label, receipt or other documentation from the other pharmacy that contains the essential information;

(b) after a reasonable effort, the pharmacist or DMP is unable to contact the other pharmacy to transfer the remaining prescription refills or there are no refills remaining on the prescription;

(c) the pharmacist or DMP, in his or her professional judgment, determines that such a request for an emergency refill is appropriate and meets the requirements of (a) and (b) of this subsection; and

(d) the pharmacist or DMP complies with the requirements of Subsections (11)(c) through (g) of this section.

(13) The address specified in Subsection 58-17b-602(1)(b) shall be a physical address, not a post office box.

(14) In accordance with Subsection 58-37-6(7)(e), a prescription may not be written, issued, filled, or dispensed for a Schedule I controlled substance unless:

(a) the person who writes the prescription is licensed to prescribe Schedule I controlled substances; and

(b) the prescribed controlled substance is to be used in research.


In accordance with Subsections 58-17b-102(29) through (30), 58-17b-602(1), R156-82, and R156-1, prescription orders may be issued by electronic means of communication according to the following standards:

(1) Prescription orders for Schedule II - V controlled substances received by electronic means of communication shall be handled according to Part 1304.04 of Section 21 of the CFR.

(2) Prescription orders for non-controlled substances received by electronic means of communication may be dispensed by a pharmacist, pharmacy intern, or DMP only if all of the following conditions are satisfied:

(a) all electronically transmitted prescription orders shall include the following:

(i) all information that is required to be contained in a prescription order pursuant to Section 58-17b-602;

(ii) the time and date of the transmission, and if a facsimile transmission, the electronically encoded date, time and fax number of the sender; and

(iii) the name of the pharmacy intended to receive the transmission;

(b) the prescription order shall be transmitted under the direct supervision of the prescribing practitioner or his designated
agent;
(c) the pharmacist or DMP shall exercise professional judgment regarding the accuracy and authenticity of the transmitted prescription. Practitioners or their agents transmitting medication orders using electronic equipment are to provide voice verification when requested by the pharmacist receiving the medication order. The pharmacist or DMP is responsible for assuring that each electronically transferred prescription order is valid and shall authenticate a prescription order issued by a prescribing practitioner that has been transmitted to the dispensing pharmacy before filling it, whenever there is a question;
(d) a practitioner may authorize an agent to electronically transmit a prescription provided that the identifying information of the transmitting agent is included on the transmission. The practitioner's electronic signature, or other secure method of validation, shall be provided with the electronic prescription; and
(e) an electronically transmitted prescription order that meets the requirements above shall be deemed to be the original prescription.

(3) This section does not apply to the use of electronic equipment to transmit prescription orders within inpatient medical facilities.

(4) No agreement between a prescribing practitioner and a pharmacy shall require that prescription orders be transmitted by electronic means from the prescribing practitioner to that pharmacy only.

(5) The pharmacist or DMP shall retain a printed copy of an electronic prescription, or a record of an electronic prescription that is readily retrievable and printable, for a minimum of five years. The printed copy shall be of non-fading legibility.

(6) Wholesalers, distributors, manufacturers, pharmacists and pharmacies shall not supply electronic equipment to any prescriber for transmitting prescription orders.

(7) An electronically transmitted prescription order shall be transmitted to the pharmacy of the patient's choice.

(8) Prescription orders electronically transmitted to the pharmacy by the patient shall not be filled or dispensed.

(9) A prescription order for a legend drug or controlled substance in Schedule III through V may be transferred up to the maximum refills permitted by law or by the prescriber by electronic transmission providing the pharmacies share a real-time, on-line database provided that:

(a) the information required to be on the transferred prescription has the same information as described in Subsection R156-17b-612(5)(a) through (f); and

(b) pharmacists, pharmacy interns, pharmacy technicians, or pharmacy technician trainees, DMPs, and DMP designees electronically accessing the same prescription drug order records may electronically transfer prescription information if the data processing system has a mechanism to send a message to the transferring pharmacy containing the following information:

(i) the fact that the prescription drug order was transferred;

(ii) the unique identification number of the prescription drug order transferred;

(iii) the name of the pharmacy to which it was transferred; and

(iv) the date and time of the transfer.


(1) In accordance with Subsection 58-17b-601(1), the following operating standards apply to all Class A and Class B pharmacies, which may be supplemented by additional standards defined in this rule applicable to specific types of Class A and B pharmacies. The general operating standards include:

(a) shall be well lighted, well ventilated, clean and sanitary;

(b) if transferring a drug from a manufacturer's or distributor's original container to another container, the dispensing area, if any, shall have a sink with hot and cold culinary water separate and apart from any restroom facilities. This does not apply to clean rooms where sterile products are prepared. Clean rooms should not have sinks or floor drains that expose the area to an open sewer. All required equipment shall be clean and in good operating condition;

(c) be equipped to permit the orderly storage of prescription drugs and durable medical equipment in a manner to permit clear identification, separation and easy retrieval of products and an environment necessary to maintain the integrity of the product inventory;

(d) be equipped to permit practice within the standards and ethics of the profession as dictated by the usual and ordinary scope of practice to be conducted within that facility;

(e) be stocked with the quality and quantity of product necessary for the facility to meet its scope of practice in a manner consistent with the public health, safety and welfare; and

(f) if dispensing controlled substances, be equipped with a security system to:

(i) permit detection of entry at all times when the facility is closed; and

(ii) provide notice of unauthorized entry to an individual; and

(g) be equipped with a lock on any entrances to the facility where drugs are stored.

(2) The temperature of the pharmacy shall be maintained within a range compatible with the proper storage of drugs. If a refrigerator or freezer is necessary to properly store drugs at the pharmacy, the pharmacy shall keep a daily written or electronic log of the temperature of the refrigerator or freezer on days of operation. The pharmacy shall retain each log entry for at least three years.

(3) Facilities engaged in simple, moderate or complex non-sterile or any level of sterile compounding activities shall be required to maintain proper records and procedure manuals and establish quality control measures to ensure stability, equivalency
where applicable and sterility. The following requirements shall be met:

(a) Facilities shall follow USP-NF Chapter 795, compounding of non-sterile preparations, and USP-NF Chapter 797 if compounding sterile preparations.

(b) Facilities may compound in anticipation of receiving prescriptions in limited amounts.

(c) Bulk active ingredients shall:
   (i) be procured from a facility registered with the federal Food and Drug Administration; and
   (ii) not be listed on the federal Food and Drug Administration list of drug products withdrawn or removed from the market for reasons of safety or effectiveness.

(d) All facilities that dispense prescriptions must comply with the record keeping requirements of their State Boards of Pharmacy. When a facility compounds a preparation according to the manufacturer's labeling instructions, then further documentation is not required. All other compounded preparations require further documentation as described in this section.

(e) A master formulation record shall be approved by a pharmacist or DMP for each batch of sterile or non-sterile pharmaceuticals to be prepared. Once approved, a duplicate of the master formulation record shall be used as the compounding record from which each batch is prepared and on which all documentation for that batch occurs. The master formulation record may be stored electronically and shall contain at a minimum:

   (i) official or assigned name;
   (ii) strength;
   (iii) dosage form of the preparation;
   (iv) calculations needed to determine and verify quantities of components and doses of active pharmaceutical ingredients;
   (v) description of all ingredients and their quantities;
   (vi) compatibility and stability information, including references when available;
   (vii) equipment needed to prepare the preparation;
   (viii) mixing instructions, which shall include:
       (A) order of mixing;
       (B) mixing temperatures or other environmental controls;
       (C) duration of mixing; and
       (D) other factors pertinent to the replication of the preparation as compounded;
   (ix) sample labeling information, which shall contain, in addition to legally required information:
       (A) generic name and quantity or concentration of each active ingredient;
       (B) assigned beyond use date;
       (C) storage conditions; and
       (D) prescription or control number, whichever is applicable;
   (x) container used in dispensing;
   (xi) packaging and storage requirements;
   (xii) description of final preparation; and
   (xiii) quality control procedures and expected results.

(f) A compounding record for each batch of sterile or non-sterile pharmaceuticals shall document the following:

   (i) official or assigned name;
   (ii) strength and dosage of the preparation;
   (iii) Master Formulation Record reference for the preparation;
   (iv) names and quantities of all components;
   (v) sources, lot numbers, and expiration dates of components;
   (vi) total quantity compounded;
   (vii) name of the person who prepared the preparation;
   (viii) name of the compounder who approved the preparation;
   (ix) name of the person who performed the quality control procedures;
   (x) date of preparation;
   (xi) assigned control, if for anticipation of use or prescription number, if patient specific, whichever is applicable;
   (xii) duplicate label as described in the Master Formulation Record means the sample labeling information that is dispensed on the final product given to the patient and shall at minimum contain:
       (A) active ingredients;
       (B) beyond-use-date;
       (C) storage conditions; and
       (D) lot number;
   (xiii) proof of the duplicate labeling information, which proof shall:
       (A) be kept at the pharmacy;
       (B) be immediately retrievable;
       (C) include an audit trail for any altered form; and
       (D) be reproduced in:
(I) the original format that was dispensed;  
(II) an electronic format; or  
(III) a scanned electronic version;  
(xvii) description of final preparation;  
(xviii) results of quality control procedures (e.g. weight range of filled capsules, pH of aqueous liquids); and  
(xix) documentation of any quality control issues and any adverse reactions or preparation problems reported by the patient or caregiver.

(g) The label of each batch prepared of sterile or non-sterile pharmaceuticals shall bear at a minimum:  
(i) the unique lot number assigned to the batch;  
(ii) all active solution and ingredient names, amounts, strengths and concentrations, when applicable;  
(iii) quantity;  
(iv) beyond use date and time, when applicable;  
(v) appropriate ancillary instructions, such as storage instructions or cautionary statements, including cytotoxic warning labels where appropriate; and  
(vi) device-specific instructions, where appropriate.  
(h) All prescription labels for compounded sterile and non-sterile medications when dispensed to the ultimate user or agent shall bear at a minimum in addition to what is required in Section 58-17b-602 the following:  
(i) generic name and quantity or concentration of each active ingredient. In the instance of a sterile preparation for parenteral use, labeling shall include the name and base solution for infusion preparation;  
(ii) assigned compounding record or lot number; and  
(iii) "this is a compounded preparation" or similar language.

(i) The beyond use date assigned shall be based on currently available drug stability information and sterility considerations or appropriate in-house or contract service stability testing:  
(ii) sources of drug stability information shall include the following:  
(A) references can be found in Trissel's "Handbook on Injectable Drugs", 17th Edition, October 31, 2012;  
(B) manufacturer recommendations; and  
(C) reliable, published research;  
(ii) when interpreting published drug stability information, the pharmacist or DMP shall consider all aspects of the final sterile product being prepared such as drug reservoir, drug concentration and storage conditions; and  
(iii) methods for establishing beyond use dates shall be documented; and  
(j) There shall be a documented, ongoing quality control program that monitors and evaluates personnel performance, equipment and facilities that follows the USP-NF Chapters 795 and 797 standards.

(4) The facility shall have current and retrievable editions of the following reference publications in print or electronic format and readily available and retrievable to facility personnel:  
(a) Title 58, Chapter 1, Division of Occupational and Professional Licensing Act  
(b) R156-1, General Rule of the Division of Occupational and Professional Licensing;  
(c) Title 58, Chapter 17b, Pharmacy Practice Act;  
(d) R156-17b, Utah Pharmacy Practice Act Rule;  
(e) Title 58, Chapter 37, Utah Controlled Substances Act;  
(f) R156-37, Utah Controlled Substances Act Rule;  
(g) Title 58, Chapter 37f, Controlled Substance Database Act;  
(h) R156-37f, Controlled Substance Database Act Rule;  
(i) Code of Federal Regulations (CFR) 21, Food and Drugs, Part 1300 to end or equivalent such as the USP DI Drug Reference Guides;  
(j) current FDA Approved Drug Products (orange book); and  
(k) any other general drug references necessary to permit practice dictated by the usual and ordinary scope of practice to be conducted within that facility.

(5) The facility shall maintain a current list of licensed employees involved in the practice of pharmacy at the facility. The list shall include individual licensee names, license classifications, license numbers, and license expiration dates. The list shall be readily retrievable for inspection by the Division and may be maintained in paper or electronic form.

(6) Facilities shall have a counseling area to allow for confidential patient counseling, where applicable.

(7) A pharmacy shall not dispense a prescription drug or device to a patient unless a pharmacist or DMP is physically present and immediately available in the facility.

(8) Only a licensed Utah pharmacist, DMP or authorized pharmacy personnel shall have access to the pharmacy when the pharmacy is closed.

(9) The facility or parent company shall maintain a record for not less than 5 years of the initials or identification codes that identify each dispensing pharmacist or DMP by name. The initials or identification code shall be unique to ensure that each pharmacist or DMP can be identified; therefore identical initials or identification codes shall not be used.

(10) The pharmacy facility shall maintain copy 3 of DEA order form (Form 222) that has been properly dated, initialed and
filed and all copies of each unaccepted or defective order form and any attached statements or other documents.

(11) If applicable, a hard copy of the power of attorney authorizing a pharmacist, DMP, or DMP designee to sign DEA order forms (Form 222) shall be available to the Division whenever necessary.

(12) A pharmacist, DMP or other responsible individual shall verify that controlled substances are listed on the suppliers' invoices and were actually received by clearly recording their initials and the actual date of receipt of the controlled substances.

(13) The pharmacy facility shall maintain a record of suppliers' credit memos for controlled substances.

(14) A copy of inventories required under Section R156-17b-605 shall be made available to the Division when requested.

(15) The pharmacy facility shall maintain hard copy reports of surrender or destruction of controlled substances and legend drugs submitted to appropriate state or federal agencies.

(16) If the pharmacy does not store drugs in a locked cabinet and has a drop/false ceiling, the pharmacy's perimeter walls shall extend to the hard deck, or other measures shall be taken to prevent unauthorized entry into the pharmacy.

R156-17b-614b. Operating Standards - Class B pharmacy designated as a Branch Pharmacy.

In accordance with Subsections 58-17b-102(8) and 58-1-301(3), the qualifications for designation as a branch pharmacy include the following:

(1) The Division, in collaboration with the Board, shall approve the location of each branch pharmacy. The following shall be considered in granting such designation:
   (a) the distance between or from nearby alternative pharmacies and all other factors affecting access of persons in the area to alternative pharmacy resources;
   (b) the availability at the location of qualified persons to staff the pharmacy, including the physician, physician assistant or advanced practice registered nurse;
   (c) the availability and willingness of a parent pharmacy and supervising pharmacist to assume responsibility for the branch pharmacy;
   (d) the availability of satisfactory physical facilities in which the branch pharmacy may operate; and
   (e) the totality of conditions and circumstances which surround the request for designation.

(2) A branch pharmacy shall be licensed as a pharmacy branch of an existing Class A or B pharmacy licensed by the Division.

(3) The application for designation of a branch pharmacy shall be submitted by the licensed parent pharmacy seeking such designation. In the event that more than one licensed pharmacy makes application for designation of a branch pharmacy location at a previously undesignated location, the Division in collaboration with the Board shall review all applications for designation of the branch pharmacy and, if the location is approved, shall approve for licensure the applicant determined best able to serve the public interest as identified in Subsection (1).

(4) The application shall include the following:
   (a) complete identifying information concerning the applying parent pharmacy;
   (b) complete identifying information concerning the designated supervising pharmacist employed at the parent pharmacy;
   (c) address and description of the facility in which the branch pharmacy is to be located;
   (d) specific formulary to be stocked indicating with respect to each prescription drug, the name, the dosage strength and dosage units in which the drug will be prepackaged;
   (e) complete identifying information concerning each person located at the branch pharmacy who will dispense prescription drugs in accordance with the approved protocol; and
   (f) protocols under which the branch pharmacy will operate and its relationship with the parent pharmacy to include the following:
      (i) the conditions under which prescription drugs will be stored, used and accounted for;
      (ii) the method by which the drugs will be transported from parent pharmacy to the branch pharmacy and accounted for by the branch pharmacy; and
      (iii) a description of how records will be kept with respect to:
         (A) formulary;
         (B) changes in formulary;
         (C) record of drugs sent by the parent pharmacy;
         (D) record of drugs received by the branch pharmacy;
         (E) record of drugs dispensed;
         (F) periodic inventories; and
         (G) any other record contributing to an effective audit trail with respect to prescription drugs provided to the branch pharmacy.

R156-17b-614c. Operating Standards - Class B - Pharmaceutical Administration Facility.

In accordance with Subsections 58-17b-102(44) and 58-17b-601(1), the following applies with respect to prescription drugs which are held, stored or otherwise under the control of a pharmaceutical administration facility for administration to patients:

(1) The licensed pharmacist shall provide consultation on all aspects of pharmacy services in the facility; establish a system
of records of receipt and disposition of all controlled substances in sufficient detail to enable an accurate reconciliation; and determine that drug records are in order and that an account of all controlled substances is maintained and periodically reconciled.

(2) Authorized destruction of all prescription drugs shall be witnessed by the medical or nursing director or a designated physician, registered nurse or other licensed person employed in the facility and the consulting pharmacist or licensed pharmacy technician and must be in compliance with DEA regulations.

(3) Prescriptions for patients in the facility can be verbally requested by a licensed prescribing practitioner and may be entered as the prescribing practitioner's order; but the practitioner must personally sign the order in the facility record within 72 hours if a Schedule II controlled substance and within 30 days if any other prescription drug. The prescribing practitioner's verbal order may be copied and forwarded to a pharmacy for dispensing and may serve as the pharmacy's record of the prescription order.

(4) Prescriptions for controlled substances for patients in Class B pharmaceutical administration facilities shall be dispensed according to Title 58, Chapter 37, Utah Controlled Substances Act, and R156-37, Utah Controlled Substances Act Rules.

(5) Requirements for emergency drug kits shall include:
   (a) an emergency drug kit may be used by pharmaceutical administration facilities. The emergency drug kit shall be considered to be a physical extension of the pharmacy supplying the emergency drug kit and shall at all times remain under the ownership of that pharmacy;
   (b) the contents and quantity of drugs and supplies in the emergency drug kit shall be determined by the Medical Director or Director of Nursing of the pharmaceutical administration facility and the consulting pharmacist of the supplying pharmacy;
   (c) a copy of the approved list of contents shall be conspicuously posted on or near the kit;
   (d) the emergency kit shall be used only for bona fide emergencies and only when medications cannot be obtained from a pharmacy in a timely manner;
   (e) records documenting the receipt and removal of drugs in the emergency kit shall be maintained by the facility and the pharmacy;
   (f) the pharmacy shall be responsible for ensuring proper storage, security and accountability of the emergency kit and shall ensure that:
      (i) the emergency kit is stored in a locked area and is locked itself; and
      (ii) emergency kit drugs are accessible only to licensed physicians, physician assistants and nurses employed by the facility;
   (g) the contents of the emergency kit, the approved list of contents and all related records shall be made freely available and open for inspection to appropriate representatives of the Division and the Utah Department of Health.

R156-17b-614d. Operating Standards - Class B - Nuclear Pharmacy.

In accordance with Subsection 58-17b-601(1), the operating standards for a Class B pharmacy designated as a nuclear pharmacy shall have the following:

(1) A nuclear pharmacy shall have the following:
   (a) have applied for or possess a current Utah Radioactive Materials License; and
   (b) adequate space and equipment commensurate with the scope of services required and provided.

(2) Nuclear pharmacies shall only dispense radiopharmaceuticals that comply with acceptable standards of quality assurance.

(3) Nuclear pharmacies shall maintain a library commensurate with the level of radiopharmaceutical service to be provided.

(4) A licensed Utah pharmacist shall be immediately available on the premises at all times when the facility is open or available to engage in the practice of pharmacy.

(5) In addition to Utah licensure, the pharmacist shall have classroom and laboratory training and experience as required by the Utah Radiation Control Rules.

(6) This rule does not prohibit:
   (a) a licensed pharmacy intern or technician from acting under the direct supervision of an approved preceptor who meets the requirements to supervise a nuclear pharmacy; or
   (b) a Utah Radioactive Materials license from possessing and using radiopharmaceuticals for medical use.

(7) A hospital nuclear medicine department or an office of a physician/surgeon, osteopathic physician/surgeon, veterinarian, pediatric physician or dentist that has a current Utah Radioactive Materials License does not require licensure as a Class B pharmacy.

(8) A nuclear pharmacy preparing sterile compounds must follow the USP-NF Chapter 797 Compound for sterile preparations.

(9) A nuclear pharmacy preparing medications for a specific person shall be licensed as a Class B - nuclear pharmacy if located in Utah, and as a Class D pharmacy if located outside of Utah.


In accordance with Subsection 58-17b-601(1), the following operating standards apply to pharmacies that engage in central prescription processing as defined in Subsection 58-17b-102(9):

(1) Centralized prescription processing services may be performed if the parties:
   (a) have common ownership or common administrative control; or
   (b) have a written contract outlining the services to be provided and the responsibilities and accountabilities of each party in fulfilling the terms of said contract; and
(c) share a common electronic file or have appropriate technology to allow access to sufficient information necessary or
required to fill or refill a prescription drug order.

(2) The parties performing or contracting for centralized prescription processing services shall maintain a policy and
procedures manual, and documentation of implementation, which shall be made available to the Division upon inspection and which
includes the following:
   (a) a description of how the parties will comply with federal and state laws and regulations;
   (b) appropriate records to identify the responsible pharmacists and the dispensing and counseling process;
   (c) a mechanism for tracking the prescription drug order during each step in the dispensing process;
   (d) a description of adequate security to protect the integrity and prevent the illegal use or disclosure of protected health
       information; and
   (e) a continuous quality improvement program for pharmacy services designed to objectively and systematically monitor and
evaluate the quality and appropriateness of patient care, pursue opportunities to improve patient care, and resolve identified problems.

(3) "Non drug or device handling central prescription processing pharmacies", as defined in Subsection R156-17b-102(37),
shall be licensed as Class E pharmacies. All other central prescription processing pharmacies shall be licensed in the appropriate
pharmacy license classification.

R156-17b-615. Operating Standards - Class C Pharmacy - Pharmaceutical Wholesaler/Distributor and Pharmaceutical
Manufacturer.

In accordance with Subsections 58-17b-102(47) and 58-17b-601(1), the operating standards for Class C pharmacies
designated as pharmaceutical wholesaler/distributor and pharmaceutical manufacturer licensees includes the following:

(1) Each pharmaceutical wholesaler or manufacturer that distributes or manufactures drugs or medical devices in Utah shall
be licensed by the Division. A separate license shall be obtained for each separate location engaged in the distribution or
manufacturing of prescription drugs. Business names cannot be identical to the name used by another unrelated wholesaler licensed to
purchase drugs and devices in Utah.

(2) Manufacturers distributing only their own FDA-approved:
   (a) prescription drugs or prescription drugs that are co-licensed products satisfy the requirement in Subsection (1) by
       registering their establishment with the FDA pursuant to 21 CFR Part 207 and submitting the information required by 21 CFR Part
       205 including any amendments thereto, to the Division; or
   (b) devices or devices that are co-licensed products, including products packaged with devices, such as convenience kits, that
       are exempt from the definition of transaction in 21 USC sec. 360eee (24)(B)(xi-xvi) satisfy the requirement in Subsection (1) by
       registering their establishment with the FDA pursuant to 21 CFR.

(3) An applicant for licensure as a pharmaceutical wholesale distributor shall provide the following minimum information:
   (a) All trade or business names used by the licensee (including "doing business as" and "formerly known as");
   (b) Name of the owner and operator of the license as follows:
      (i) if a person, the name, business address, social security number and date of birth;
      (ii) if a partnership, the name, business address, and social security number and date of birth of each partner, and the
          partnership's federal employer identification number;
      (iii) if a corporation, the name, business address, social security number and date of birth, and title of each corporate officer
          and director, the corporate names, the name of the state of incorporation, federal employer identification number, and the name of the
          parent company, if any, but if a publicly traded corporation, the social security number and date of birth for each corporate officer
          shall not be required;
      (iv) if a sole proprietorship, the full name, business address, social security number and date of birth of the sole proprietor
          and the name and federal employer identification number of the business entity;
      (v) if a limited liability company, the name of each member, social security number of each member, the name of each
          manager, the name of the limited liability company and federal employer identification number, and the name of the state where the
          limited liability company was organized; and
      (c) any other relevant information required by the Division.

(4) The licensed facility need not be under the supervision of a licensed pharmacist, but shall be under the supervision of a
designated representative who meets the following criteria:
   (a) is at least 21 years of age;
   (b) has been employed full time for at least three years in a pharmacy or with a pharmaceutical wholesaler in a capacity
       related to the dispensing and distribution of, and recordkeeping related to prescription drugs;
   (c) is employed by the applicant full time in a managerial level position;
   (d) is actively involved in and aware of the actual daily operation of the pharmaceutical wholesale distribution;
   (e) is physically present at the facility during regular business hours, except when the absence of the designated
       representative is authorized, including but not limited to, sick leave and vacation leave; and
   (f) is serving in the capacity of a designated representative for only one licensee at a time.

(5) The licensee shall provide the name, business address, and telephone number of a person to serve as the designated
representative for each facility of the pharmaceutical wholesaler that engages in the distribution of drugs or devices.
(6) All pharmaceutical wholesalers and manufacturer shall publicly display or have readily available all licenses and the most recent inspection report administered by the Division.

(2) All Class C pharmacies shall:
   (a) be of suitable size and construction to facilitate cleaning, maintenance and proper operations;
   (b) have storage areas designed to provide adequate lighting, ventilation, sanitation, space, equipment and security conditions;
   (c) have the ability to control temperature and humidity within tolerances required by all prescription drugs and prescription drug precursors handled or used in the distribution or manufacturing activities of the applicant or licensee;
   (d) provide for a quarantine area for storage of prescription drugs and prescription drug precursors that are outdated, damaged, deteriorated, misbranded, adulterated, opened or unsealed containers that have once been appropriately sealed or closed or in any other way unsuitable for use or entry into distribution or manufacturing;
   (e) be maintained in a clean and orderly condition; and
   (f) be free from infestation by insects, rodents, birds or vermin of any kind.

(8) Each facility used for wholesale drug distribution or manufacturing of prescription drugs shall:
   (a) be secure from unauthorized entry;
   (b) limit access from the outside to a minimum in conformance with local building codes, life and safety codes and control access to persons to ensure unauthorized entry is not made;
   (c) limit entry into areas where prescription drugs, prescription drug precursors, or prescription drug devices are held to authorized persons who have a need to be in those areas;
   (d) be well lighted on the outside perimeter;
   (e) be equipped with an alarm system to permit detection of entry and notification of appropriate authorities at all times when the facility is not occupied for the purpose of engaging in distribution or manufacturing of prescription drugs; and
   (f) be equipped with security measures, systems and procedures necessary to provide reasonable security against theft and diversion of prescription drugs or alteration or tampering with computers and records pertaining to prescription drugs or prescription drug precursors.

(9) Each facility shall provide the storage of prescription drugs, prescription drug precursors, and prescription drug devices in accordance with the following:
   (a) all prescription drugs and prescription drug precursors shall be stored at appropriate temperature, humidity and other conditions in accordance with labeling of such prescription drugs or prescription drug precursors or with requirements in the USP-NF;
   (b) if no storage requirements are established for a specific prescription drug, prescription drug precursor, or prescription drug devices, the products shall be held in a condition of controlled temperature and humidity as defined in the USP-NF to ensure that its identity, strength, quality and purity are not adversely affected; and
   (c) there shall be established a system of manual, electromechanical or electronic recording of temperature and humidity in the areas in which prescription drugs, prescription drug precursors, and prescription drug devices are held to permit review of the record and ensure that the products have not been subjected to conditions that are outside of established limits.

(10) Each person who is engaged in pharmaceutical wholesale distribution of prescription drugs for human use that leave, or have ever left, the normal distribution channel shall, before each pharmaceutical wholesale distribution of such drug, provide a pedigree to the person who receives such drug. A retail pharmacy or pharmacy warehouse shall comply with the requirements of this section only if the pharmacy engages in pharmaceutical wholesale distribution of prescription drugs. The pedigree shall:
   (a) include all necessary identifying information concerning each sale in the chain of distribution of the product from the manufacturer, through acquisition and sale by any pharmaceutical wholesaler, until sale to a pharmacy or other person dispensing or administering the prescription drug. At a minimum, the necessary chain of distribution information shall include:
      (i) name, address, telephone number, and if available, the email address of each owner of the prescription drug, and each pharmaceutical wholesaler of the prescription drug;
      (ii) name and address of each location from which the product was shipped, if different from the owner's;
      (iii) transaction dates;
      (iv) name of the prescription drug;
      (v) dosage form and strength of the prescription drug;
      (vi) size of the container;
      (vii) number of containers;
      (viii) lot number of the prescription drug;
      (ix) name of the manufacturer of the finished dose form; and
      (x) National Drug Code (NDC) number.
   (b) be maintained by the purchaser and the pharmaceutical wholesaler for five years from the date of sale or transfer and be available for inspection or use upon a request of an authorized officer of the law.

(11) Each facility shall comply with the following requirements:
   (a) in general, each person who is engaged in pharmaceutical wholesale distribution of prescription drugs shall establish and maintain inventories and records of all transactions regarding the receipt and distribution or other disposition of the prescription drugs. These records shall include pedigrees for all prescription drugs that leave the normal distribution channel;
(b) upon receipt, each outside shipping container containing prescription drugs, prescription drug precursors, or prescription drug devices shall be visibly examined for identity and to prevent the acceptance of prescription drugs, prescription drug precursors, or prescription drug devices that are contaminated, reveal damage to the containers or are otherwise unfit for distribution:

(i) prescription drugs, prescription drug precursors, or prescription drug devices that are outdated, damaged, deteriorated, misbranded, adulterated or in any other way unfit for distribution or use in manufacturing shall be quarantined and physically separated from other prescription drugs, prescription drug precursors or prescription drug devices until they are appropriately destroyed or returned to their supplier; and

(ii) any prescription drug or prescription drug precursor whose immediate sealed or outer secondary sealed container has been opened or in any other way breached shall be identified as such and shall be quarantined and physically separated from other prescription drugs and prescription drug precursors until they are appropriately destroyed or returned to their supplier;

(c) each outgoing shipment shall be carefully inspected for identity of the prescription drug products or devices and to ensure that there is no delivery of prescription drugs or devices that have been damaged in storage or held under improper conditions:

(i) if the conditions or circumstances surrounding the return of any prescription drug or prescription drug precursor cast any doubt on the product's safety, identity, strength, quality or purity, then the drug shall be appropriately destroyed or returned to the supplier, unless examination, testing or other investigation proves that the product meets appropriate and applicable standards related to the product's safety, identity, strength, quality and purity;

(ii) returns of expired, damaged, recalled, or otherwise non-saleable prescription drugs shall be distributed by the receiving pharmaceutical wholesale distributor only to the original manufacturer or a third party returns processor that is licensed as a pharmaceutical wholesale distributor under this chapter;

(iii) returns or exchanges of prescription drugs (saleable or otherwise), including any redistribution by a receiving pharmaceutical wholesaler, shall not be subject to the pedigree requirements, so long as they are exempt from the pedigree requirement under the FDA's Prescription Drug Marketing Act guidance or regulations; and

(d) if licensees under this Act and pharmacies or other persons authorized by law to dispense or administer prescription drugs for use by a patient shall be accountable for administering their returns process and ensuring that all aspects of their operation are secure and do not permit the entry of adulterated and counterfeit prescription drugs.

12. A manufacturer or pharmaceutical wholesaler shall furnish prescription drugs only to a person licensed by the Division or to another appropriate state licensing authority to possess, dispense or administer such drugs for use by a patient.

13. Prescription drugs furnished by a manufacturer or pharmaceutical wholesaler shall be delivered only to the business address of a person described in Subsections R156-17b-102(19)(c) and R156-17b-615(13), or to the premises listed on the license, or to an authorized person or agent of the licensee at the premises of the manufacturer or pharmaceutical wholesaler if the identity and authority of the authorized agent is properly established.

14. Each facility shall establish and maintain records of all transactions regarding the receipt and distribution or other disposition of prescription drugs and prescription drug precursors and shall make inventories of prescription drugs and prescription drug precursors and required records available for inspection by authorized representatives of the federal, state and local law enforcement agencies in accordance with the following:

(a) there shall be a record of the source of the prescription drugs or prescription drug precursors to include the name and principal address of the seller or transferor and the address of the location from which the drugs were shipped;

(b) there shall be a record of the identity and quantity of the prescription drug or prescription drug precursor received, manufactured, distributed or shipped or otherwise disposed of by specific product and strength;

(c) there shall be a record of the dates of receipt and distribution or other disposal of any product;

(d) there shall be a record of the identity of persons to whom distribution is made to include name and principal address of the receiver and the address of the location to which the products were shipped;

(e) inventories of prescription drugs and prescription drug precursors shall be made available during regular business hours to authorized representatives of federal, state and local law enforcement authorities;

(f) required records shall be made available for inspection during regular business hours to authorized representatives of federal, state and local law enforcement authorities and such records shall be maintained for a period of two years following disposition of the products; and

(g) records that are maintained on site or immediately retrievable from computer or other electronic means shall be made readily available for authorized inspection during the retention period; or if records are stored at another location, they shall be made available within two working days after request by an authorized law enforcement authority during the two year period of retention.

15. Each facility shall establish, maintain and adhere to written policies and procedures that shall be followed for the receipt, security, storage, inventory, manufacturing, distribution or other disposal of prescription drugs or prescription drug precursors, including policies and procedures for identifying, recording and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. In addition, the policies shall include the following:

(a) a procedure whereby the oldest approved stock of a prescription drug or precursor product is distributed or used first with a provision for deviation from the requirement if such deviation is temporary and appropriate;

(b) a procedure to be followed for handling recalls and withdrawals of prescription drugs adequate to deal with recalls and withdrawals due to:

(i) any action initiated at the request of the FDA or other federal, state or local law enforcement or other authorized
administrative or regulatory agency;

(ii) any voluntary action to remove defective or potentially defective drugs from the market; or

(iii) any action undertaken to promote public health, safety or welfare by replacement of existing product with an improved product or new package design;

(c) a procedure to prepare for, protect against or handle any crisis that affects security or operation of any facility in the event of strike, fire, flood or other natural disaster or other situations of local, state or national emergency;

(d) a procedure to ensure that any outdated prescription drugs or prescription drug precursors shall be segregated from other drugs or precursors and either returned to the manufacturer, other appropriate party or appropriately destroyed;

(e) a procedure for providing for documentation of the disposition of outdated, adulterated or otherwise unsafe prescription drugs or prescription drug precursors and the maintenance of that documentation available for inspection by authorized federal, state or local authorities for a period of five years after disposition of the product;

(f) a procedure for identifying, investigating and reporting significant drug inventory discrepancies (involving counterfeit drugs suspected of being counterfeit, contraband, or suspect of being contraband) and reporting of such discrepancies within three (3) business days to the Division and/or appropriate federal or state agency upon discovery of such discrepancies; and

(g) a procedure for reporting criminal or suspected criminal activities involving the inventory of drugs and devices to the Division, FDA and if applicable, Drug Enforcement Administration (DEA), within three (3) business days.

(16) Each facility shall establish, maintain and make available for inspection by authorized federal, state and local law enforcement authorities, lists of all officers, directors, managers and other persons in charge which lists shall include a description of their duties and a summary of their background and qualifications.

(17) Each facility shall comply with laws including:

(a) operating within applicable federal, state and local laws and regulations;

(b) permitting the state licensing authority and authorized federal, state and local law enforcement officials, upon presentation of proper credentials, to enter and inspect their premises and delivery vehicles and to audit their records and written operating policies and procedures, at reasonable times and in a reasonable manner, to the extent authorized by law; and

(c) obtaining a controlled substance license from the Division and registering with the Drug Enforcement Administration (DEA) if they engage in distribution or manufacturing of controlled substances and shall comply with all federal, state and local regulations applicable to the distribution or manufacturing of controlled substances.

(18) Each facility shall be subject to and shall abide by applicable federal, state and local laws that relate to the salvaging or reprocessing of prescription drug products.

(19) A Class C pharmacy shall not be located in the same building as a separately licensed Class A, B, D, or E pharmacy unless the two pharmacies are located in different suites as recognized by the United States Postal Service. Two Class C pharmacies may be located at the same address in the same suite if the pharmacies:

(a) are under the same ownership;

(b) have processes and systems for separating and securing all aspects of the operation; and

(c) have traceability with a clear audit trail that distinguishes a pharmacy's purchases and distributions.

**R156-17b-616. Operating Standards - Class D Pharmacy - Out of State Mail Order Pharmacies.**

(1) In accordance with Subsections 58-1-301(3) and 58-17b-306(2), an application for licensure as a Class D pharmacy shall include:

(a) a pharmacy care protocol that includes the operating standards established in Subsections R156-17b-610(1) and (8) and R156-17b-612(1) through (4);

(b) a copy of the pharmacist's license for the PIC; and

(c) a copy of the most recent state inspection or NABP inspection completed as part of the NABP Verified Pharmacy Program (VPP) showing the status of compliance with the laws and regulations for physical facility, records and operations.

(2) An out of state mail order pharmacy that compounds shall follow the USP-NF Chapter 795 Compounding of non-sterile preparations and Chapter 797 Compounding of sterile preparations.

**R156-17b-617a. Class E Pharmacy Operating Standards - General Provisions.**

(1) In accordance with Section 58-17b-302 and Subsection 58-17b-601(1), Class E pharmacies shall have a written pharmacy care protocol that includes:

(a) the identity of the supervisor or director;

(b) a detailed plan of care;

(c) the identity of the drugs to be purchased, stored, used and accounted for; and

(d) the identity of any licensed healthcare provider associated with the operation.

(2) Class E pharmacies shall comply with all applicable federal and state laws.

**R156-17b-617b. Class E Pharmacy Operating Standards – Analytical Laboratory.**

In accordance with Section 58-17b-302 and Subsection 58-17b-601(1), an analytical laboratory shall:

(1) be of suitable size and construction to facilitate cleaning, maintenance and proper operations;
(2) provide adequate lighting, ventilation, sanitation, space, equipment and security conditions;
(3) maintain a list of drugs that will be purchased, stored, used and accounted for;
(4) maintain a list of licensed healthcare providers associated with the operation of the business;
(5) possess prescription drugs for the purpose of analysis; and
(6) take measures to prevent the theft or loss of controlled substances.

R156-17b-617c. Class E Pharmacy Operating Standards – Animal Control or Animal Narcotic Detection Training.
(1) In accordance with Section 58-17b-302 and Subsection 58-17b-601(1), an animal control or animal narcotic detection training facility shall:
   (a) maintain for immediate retrieval a perpetual inventory of all drugs including controlled substances that are purchased, stored, processed and administered;
   (b) maintain for immediate retrieval a current list of authorized employees and their training with regards to the handling and use of legend drugs and/or controlled substances in relation to euthanasia, immobilization, or narcotic detection training of animals;
   (c) maintain, for immediate retrieval documentation of all required materials pertaining to legitimate animal scientific drug research, guidance policy and other relevant documentation from the agency’s Institutional Review Board, if applicable;
   (d) maintain stocks of legend drugs and controlled substances to the smallest quantity needed for efficient operation to conduct animal euthanasia, immobilization, or narcotic detection training purposes;
   (e) maintain all legend drugs and controlled substances in an area within a building having perimeter security that limits access during working hours, provides adequate security after working hours, and has the following security controls:
      (i) a permanently secured safe or steel cabinet substantially constructed with self-closing and self-locking doors employing either multiple position combination or key lock type locking mechanisms; and
      (ii) requisite key control, combination limitations, and change procedures;
   (f) have a responsible party who is the only person authorized to purchase and reconcile legend drugs and controlled substances and is responsible for the inventory of the animal control or animal narcotic detection training facility pharmacy;
   (g) ensure that only defined and approved individuals pursuant to the written facility protocol have access to legend drugs and controlled substances; and
   (h) develop and maintain written policies and procedures for immediate retrieval that include the following:
      (i) the type of activity conducted with regards to legend drugs and/or controlled substances;
      (ii) how medications are purchased, inventoried, prepared and used in relation to euthanasia, immobilization, or narcotic detection training of animals;
      (iii) the type, form and quantity of legend drugs and/or controlled substances handled;
      (iv) the type of safe or equally secure enclosures or other storage system used for the storage and retrieval of legend drugs and/or controlled substances;
      (v) security measures in place to protect against theft or loss of legend drugs and controlled substances;
      (vi) adequate supervision of employees having access to manufacturing and storage areas;
      (vii) maintenance of records documenting the initial and ongoing training of authorized employees with regard to all applicable protocols;
      (viii) maintenance of records documenting all approved and trained authorized employees who may have access to the legend drugs and controlled substances; and
      (ix) procedures for allowing the presence of business guests, visitors, maintenance personnel, and non-employee service personnel.

R156-17b-617d. Class E Pharmacy Operating Standards– Durable Medical Equipment.
(1) In accordance with Section 58-17b-302 and Subsection 58-17b-601(1), durable medical equipment facility shall:
   (a) be of suitable size and construction to facilitate cleaning, maintenance and proper operations;
   (b) provide adequate lighting, ventilation, sanitation, space, equipment and security conditions;
   (c) be equipped to permit the orderly storage of durable medical equipment in a manner to permit clear identification, separation and easy retrieval of products and an environment necessary to maintain the integrity of the product inventory;
   (d) be equipped to permit practice within the standards and ethics of the profession as dictated by the usual and ordinary scope of practice to be conducted within that facility;
   (e) maintain prescription forms and records for a period of five years;
   (f) be locked and enclosed in such a way as to bar entry by the public or any non-personnel when the facility is closed; and
   (g) post the license of the facility in full view of the public.
(2) A licensed practitioner who administers durable medical equipment to a patient or animal is not engaging in the practice of pharmacy, and does not require a license as a Class E pharmacy.

R156-17b-617e. Class E Pharmacy Operating Standards – Human Clinical Investigational Drug Research Facility
(1) In accordance with Section 58-17b-302 and Subsection 58-17b-601(1), a human clinical investigational drug research facility licensed as a Class E Pharmacy shall, in addition to the requirements contained in Subsection R156-17b-617a, conduct
operations in accordance with the operating standards set forth in 21 CFR Part 312, April 1, 2012 edition, which are hereby incorporated by reference.

(2) In accordance with Subsections 58-37-6(2)(b) and (3)(a)(i), persons licensed to conduct research with controlled substances in Schedules I-VI within this state may possess, manufacture, produce, distribute, prescribe, dispense, administer, conduct research with, or perform laboratory analysis upon those substances to the extent authorized by their license.

(3) In accordance with Subsection 58-37-6(2), the following persons are not required to obtain a license and may lawfully possess controlled substances included in Schedules II-V:
   (a) an agent or employee acting in the usual course of the person’s business or employment, and
   (b) an ultimate user, or any person who possesses any controlled substance pursuant to a lawful order of a practitioner.

(4) A separate license is required at each principal place of business or professional practice where the applicant manufactures, produces, distributes, dispenses, conducts research with, or performs laboratory analysis upon controlled substances.

R156-17b-617f. Class E Pharmacy Operating Standards – Medical Gas Provider
In accordance with Section 58-17b-302 and Subsection 58-17b-601(1), a medical gas facility shall:
(a) develop standard operating policy and procedures manual;
(b) conduct training and maintain evidence of employee training programs and completion certificates;
(c) maintain documentation and records of all transactions to include:
   (i) batch production records
   (ii) certificates of analysis
   (iii) dates of calibration of gauges;
(d) provide adequate space for orderly placement of equipment and finished product;
(e) maintain gas tanks securely;
(f) designate return and quarantine areas for separation of products;
(g) label all products;
(h) fill cylinders without using adapters; and
(i) comply with all FDA standards and requirements.

R156-17b-618. Change in Ownership or Location.
(1) In accordance with Section 58-17b-614, except for changes in ownership caused by a change in the stockholders in corporations that are publicly listed and whose stock is publicly traded, a licensed pharmaceutical facility shall make application for a new license and receive approval from the Division no later than ten business days prior to any of the following proposed changes:
   (a) location or address, except for a reassignment of a new address by the United States Postal Service that does not involve any change of location;
   (b) name, except for a doing-business-as (DBA) name change that is properly registered with the Division of Corporations and filed with the Division of Occupational and Professional Licensing; or
   (c) ownership when one of the following occurs:
      (i) a change in entity type; or
      (ii) the sale or transfer of 51% or more of an entity's ownership or membership interest to another individual or entity.

(2) Upon approval of the change in location, name, or ownership, and the issuance of a new license, the original license shall be surrendered to the Division.

(3) Upon approval of the name change, the original licenses shall be surrendered to the Division.

Reserved

In accordance with Section 58-17b-621, automated pharmacy systems can be utilized in licensed pharmacies, remote locations under the jurisdiction of the Division and licensed health care facilities where legally permissible and shall comply with the following provisions:
(1) Documentation as to type of equipment, serial numbers, content, policies and procedures and location shall be maintained on site in the pharmacy for review upon request of the Division. Such documentation shall include:
   (a) name and address of the pharmacy or licensed health care facility where the automated pharmacy system is being used;
   (b) manufacturer's name and model;
   (c) description of how the device is used;
   (d) quality assurance procedures to determine continued appropriate use of the automated device; and
   (e) policies and procedures for system operation, safety, security, accuracy, patient confidentiality, access and malfunction.

(2) Automated pharmacy systems should be used only in settings where there is an established program of pharmaceutical care that ensures that before dispensing, or removal from an automated storage and distribution device, a pharmacist reviews all prescription or medication orders unless a licensed independent practitioner controls the ordering, preparation and administration of
the medication; or in urgent situations when the resulting delay would harm the patient including situations in which the patient experiences a sudden change in clinical status.

(3) All policies and procedures must be maintained in the pharmacy responsible for the system and, if the system is not located within the facility where the pharmacy is located, at the location where the system is being used.

(4) Automated pharmacy systems shall have:
(a) adequate security systems and procedures to:
   (i) prevent unauthorized access;
   (ii) comply with federal and state regulations; and
   (iii) prevent the illegal use or disclosure of protected health information;
(b) written policies and procedures in place prior to installation to ensure safety, accuracy, security, training of personnel, and patient confidentiality and to define access and limits to access to equipment and medications.

(5) Records and electronic data kept by automated pharmacy systems shall meet the following requirements:
(a) all events involving the contents of the automated pharmacy system must be recorded electronically;
(b) records must be maintained by the pharmacy for a period of five years and must be readily available to the Division.

   Such records shall include:
   (i) identity of system accessed;
   (ii) identify of the individual accessing the system;
   (iii) type of transaction;
   (iv) name, strength, dosage form and quantity of the drug accessed;
   (v) name of the patient for whom the drug was ordered; and
   (vi) such additional information as the PIC may deem necessary.

(6) Access to and limits on access to the automated pharmacy system must be defined by policy and procedures and must comply with state and federal regulations.

(7) The PIC or pharmacist designee shall have the responsibility to ensure that:
(a) user access to the system is assigned, discontinued or changed according to employment status and credentials;
(b) access to the medications comply with state and federal regulations; and
(c) the automated pharmacy system is filled and stocked accurately and in accordance with established written policies and procedures.

(8) The filling and stocking of all medications in the automated pharmacy system shall be accomplished by qualified licensed healthcare personnel under the supervision of a licensed pharmacist.

(9) A record of medications filled and stocked into an automated pharmacy system shall be maintained for a period of five years and shall include the identification of the persons filling, stocking and checking for accuracy.

(10) All containers of medications stored in the automated pharmacy system shall be packaged and labeled in accordance with federal and state laws and regulations.

(11) All aspects of handling controlled substances shall meet the requirements of all state and federal laws and regulations.

(12) The automated pharmacy system shall provide a mechanism for securing and accounting for medications removed from and subsequently returned to the automated pharmacy system, all in accordance with existing state and federal law. Written policies and procedures shall address situations in which medications removed from the system remain unused and must be secured and accounted for.

(13) The automated pharmacy system shall provide a mechanism for securing and accounting for wasted medications or discarded medications in accordance with existing state and federal law. Written policies and procedures shall address situations in which medications removed from the system are wasted or discarded and must be secured.

R156-17b-621. Operating Standards - Pharmacist Administration - Training.

(1) In accordance with Subsection 58-17b-502(9), appropriate training for the administration of a prescription drug includes:
   (a) current Basic Life Support (BLS) certification; and
   (b) successful completion of a training program which includes at a minimum:
      (i) didactic and practical training for administering injectable drugs;
      (ii) the current Advisory Committee on Immunization Practices (ACIP) of the United States Center for Disease Control and Prevention guidelines for the administration of immunizations; and
      (iii) the management of an anaphylactic reaction.

(2) Sources for the appropriate training include:
   (a) ACPE approved programs; and
   (b) curriculum-based programs from an ACPE accredited college of pharmacy, state or local health department programs and other Board recognized providers.

(3) Training is to be supplemented by documentation of two hours of continuing education related to the area of practice in each preceding renewal period.

(4) The "Vaccine Administration Protocol: Standing Order to Administer Immunizations and Emergency Medications", 

\[35\]
adopted March 27, 2012, by the Division in collaboration with the Utah State Board of Pharmacy, as posted on the Division website, is the guideline or standard for pharmacist administration of vaccines and emergency medications.

**R156-17b-621a. Operating Standards - Pharmacist Administration of a Long-acting Injectable Drug Therapy - Training.**

In accordance with Subsections 58-17b-502(9) and 58-17b-625(2):
1. Training for a pharmacist to administer long-acting injectables intramuscularly shall include successful completion of:
   a. current Basic Life Support (BLS) certification; and
   b. a training program for administering long-acting injectables intramuscularly that is provided by an ACPE accredited provider.
2. An individual who engages in the administration of long-acting injectables intramuscularly shall:
   a. maintain documentation that the required training was obtained prior to any administration; and
   b. for each renewal cycle after the initial training, successfully complete a minimum of two hours of continuing education related to long-acting injectables.

**R156-17b-622. Standards - Dispensing Training Program.**

1. In accordance with Subsection R156-17b-102 (17), a formal or on-the-job dispensing training program completed by a DMP designee is one that covers the following topics to the extent that the topics are relevant and current to the DMP practice where the DMP designee is employed:
   a. role of the DMP designee;
   b. laws affecting prescription drug dispensing;
   c. pharmacology including the identification of drugs by trade and generic names, and therapeutic classifications;
   d. pharmaceutical terminology, abbreviations and symbols;
   e. pharmaceutical calculations;
   f. drug packaging and labeling;
   g. computer applications in the pharmacy;
   h. sterile and non-sterile compounding;
   i. medication errors and safety;
   j. prescription and order entry and fill process;
   k. pharmacy inventory management; and
   l. pharmacy billing and reimbursement.
2. Documentation demonstrating successful completion of a formal or on-the-job dispensing training program shall include the following information:
   a. name of individual trained;
   b. name of individual or entity that provided training;
   c. list of topics covered during the training program; and
   d. training completion date.

**R156-17b-623. Standards - Approved Cosmetic Drugs and Injectable Weight Loss Drugs for Dispensing Medical Practitioners.**

1. A cosmetic drug that may be dispensed by a DMP in accordance with Section 58-17b-803 is limited to Latisse.
2. An injectable weight loss drug that may be dispensed by a DMP in accordance with Section 58-17b-803 is limited to human chorionic gonadotropin.

**R156-17b-624. Operating Standards. Repackaged or Compounded Prescription Drugs - Sale to a Practitioner for Office Use.**

Pursuant to Section 58-17b-624, a pharmacy may repackage or compound a prescription drug for sale to a practitioner for office use provided that it is in compliance with all applicable federal and state laws and regulations regarding the practice of pharmacy, including, but not limited to the Food, Drug, and Cosmetic Act, 21 U.S.C.A § 301 et seq.

**R156-17b-625. Standards - Reporting and Maintaining Records on the Dispensing of an Opiate Antagonist.**

1. In accordance with Subsections 26-55-105(2)(c) and (d), the pharmacist-in-charge or a responsible corporate officer of each pharmacy licensee that dispenses an opiate antagonist pursuant to a valid standing prescription drug order issued by a physician, shall affirm that the pharmacy licensee has complied with the protocol for dispensing an opiate antagonist as set forth in Section 26-55-105, and shall report, on an annual basis, to the division and to the physician who issued the opiate antagonist standing drug order, the following information:
   a. the total number of single doses of opiate antagonists dispensed during the reporting period; and
   b. the name of each opiate antagonist dispensed, along with the total number of single doses of that particular named opiate antagonist.
2. Corporations or organizations with multiple component pharmacy licenses may submit one cumulative report for all its component pharmacy licensees. However, that report must contain the information described above for each of the component pharmacy licensees.
(3) Null reporting is not required. If a pharmacy licensee does not dispense an opiate antagonist during any year, that pharmacy licensee is not required to make an affirmation or report to the division.

(4) The annual affirmation and report described above is due to the division and to the physician who issued the standing drug order no later than 15 days following December 31 of each calendar year.

(5) In accordance with Subsection 26-55-105(2)(d), a pharmacy licensee who dispenses an opiate antagonist pursuant to a valid standing prescription order issued by a physician, shall maintain, subject to audit, the following information:
   (a) the name of the individual to whom the opiate antagonist is dispensed;
   (b) the name of the opiate antagonist dispensed;
   (c) the quantity of the opiate antagonist dispensed;
   (d) the strength of the opiate antagonist dispensed;
   (e) the dosage quantity of the opiate antagonist dispensed;
   (f) the full name of the drug outlet which dispensed the opiate antagonist;
   (g) the date the opiate antagonist was dispensed; and
   (h) the name of physician issuing the standing order to dispense the opiate antagonist.

(6) The division approves the protocol for the issuance of a standing prescription drug order for opiate antagonists, which is set forth in Subsection 26-55-105(2)(a) through (d) along with the requirements set forth in the foregoing provisions, and the reporting requirements set forth in Sections R156-67-604 and R156-68-604.

R156-17b-904. Criteria for Eligible Prescription Drug - Beyond-use Date or Expiration Date.
The division in collaboration with the board has not established a date later than the beyond use date or the expiration date recommended by the manufacturer for a specific prescription drug.

R156-17b-905. Fees.
As authorized by Subsection 58-17b-905(2)(e), an eligible pharmacy may charge the following handling fees:
(1) Before accepting a prescription drug under the program: $0 - $10; and
(2) Before dispensing a prescription drug under the program: $0 - $5.

R156-17b-907a. Registration Requirements - Eligible Pharmacy.
(1) A pharmacy seeking registration with the division as an eligible pharmacy shall submit an application on a form provided by the division.
(2) The division's form shall at a minimum require the applicant pharmacy to establish that:
   (a) the applicant is currently licensed and in good standing with the division;
   (b) the applicant agrees to maintain, subject to inspection by the division, written standards and procedures in compliance with Section R156-17b-907c;
   (c) the applicant agrees to create and maintain, subject to inspection by the division, a special training program in accordance with Section R156-17b-907e; and
   (d) as required by Subsection 58-17b-902(8), the applicant is operated by a county, county health department, a pharmacy under contract with a county health department, the Department of Health, the Division of Substance Abuse and Mental Health, or a charitable clinic.

R156-17b-907b. Formulary.
The formulary established under Subsection 58-17b-907(2) shall include all prescription drugs approved by the federal Food and Drug Administration that meet Section 58-17b-904 criteria, except for:
(1) controlled substances;
(2) compounded drugs; and
(3) drugs that can only be dispensed to a patient registered with the drug's manufacturer per federal Food and Drug Administration requirements.

An eligible pharmacy shall maintain written standards and procedures available for inspection by the division that:
(1) satisfy the requirements of Section 58-17b-907; and
(2) satisfy labeling requirements of Subsections 58-17b-602(5) through (8), and ensure that labels clearly identify the eligible drug was dispensed under the program.

R156-17b-907d. Standards and Procedures - Facilities and Mental Health and Substance Abuse Clients.
(1) In accordance with Subsection 58-17b-907(4)(a), the division shall schedule and facilitate an annual meeting between the Department of Health and eligible pharmacies to establish program standards and procedures for assisted living facilities and nursing care facilities; and
(2) In accordance with Subsection 58-17b-907(4)(b), the division shall schedule and facilitate an annual meeting between the Division of Substance Abuse and Mental Health and eligible pharmacies to establish program standards and procedures for mental health and substance abuse clients.

**R156-17b-907e. Special Training Program.**

An eligible pharmacy shall:

1. create and maintain a special training program that its pharmacists and licensed pharmacy technicians shall complete before participating in the program; and

2. maintain a record for at least two years of all pharmacists and licensed pharmacy technicians that have completed the special training program.

**KEY:** pharmacists, licensing, pharmacies  
**Date of Enactment or Last Substantive Amendment:** December 12, 2017  
**Notice of Continuation:** January 5, 2015  
**Authorizing, and Implemented or Interpreted Law:** 58-17b-101; 58-17b-601(1); 58-37-1; 58-1-106(1)(a); 58-1-202(1)(a)
PHARMACY PRACTICE
ACT RULE

R156-17b
Utah Administrative Code
Issued December 12, 2017

Disclaimer: The statute/rule above is an unofficial version provided for convenience only and may not be identical to the official versions on the Utah State Legislature (www.le.utah.gov) and the Utah Division of Administrative Rules (www.rules.utah.gov) websites.